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Background and Purpose Reports investigating the relationship between in-procedure blood 
pressure (BP) and outcomes in patients undergoing endovascular thrombectomy (EVT) due to 
anterior circulation stroke are sparse and contradictory.
Methods Consecutive EVT-treated adults (modern stent retrievers, BP managed in line with the 
recommendations, general anesthesia, invasive BP measurements) were evaluated for associations 
of the rate of in-procedure systolic BP (SBP) and mean arterial pressure (MAP) excursions to 
>120%/<80% of the reference values (serial measurements at anesthesia induction) and of the 
reference BP/weighted in-procedure mean BP with post-procedure imaging outcomes (ischemic 
lesion volume [ILV], hemorrhages) and 3-month functional outcome (modified Rankin Scale [mRS], 
score 0 to 2 vs. 3 to 6). 
Results Overall 164 patients (70.7% pharmacological reperfusion, 80.5% with good collaterals, 
73.8% with successful reperfusion) were evaluated for ILV (range, 0 to 581 cm3) and hemorrhages 
(incidence 17.7%). Higher rate of in-procedure SBP/MAP excursions to >120% was independently 
associated with lower ILV, while higher in-procedure mean SBP/MAP was associated with lower 
odds of hemorrhages. mRS 0-2 was achieved in 75/155 (48.4%) evaluated patients (nine had 
missing mRS data). Higher rate of SBP/MAP excursions to >120% and higher reference SBP/MAP 
were independently associated with higher odds of mRS 0-2, while higher ILV was associated with 
lower odds of mRS 0-2. Rate of SBP/MAP excursions to <80% was not associated with any 
outcome.
Conclusions In the EVT-treated patients with BP managed within the recommended limits, a better 
functional outcome might be achieved by targeting in-procedure BP that exceeds the pre-
procedure values by more than 20%.
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Introduction
Critical blood pressure (BP) values in the acute ischemic stroke 
patients undergoing reperfusion treatment are based on the 
exclusion criteria in the pivotal Phase III trials of recombinant 
human tissue plasminogen activator (rtPA).1,2 These BP limits 
were applied in the most recent endovascular thrombectomy 
(EVT) studies.3 However, there have been no randomized con-
trolled trials specifically evaluating the proposed BP limits and 
there is uncertainty whether BP level of 185/105 mm Hg as an 
exclusionary criterion for reperfusion treatments can be gener-
alized.4 Notably, studies in hypertensive patients demonstrated 
a shift of the limits of functional cerebral blood flow autoregu-
lation to higher values in patients with higher pre-stroke BP 
levels.5,6 Thus, keeping BP at a certain universally defined level 
during the most vulnerable phase of acute cerebral ischemia 
seems counterintuitive. In animals models of stroke, cerebral 
blood flow in moderately under-perfused tissue depends on 
systemic BP and any significant drop in BP is likely to compro-
mise penumbra viability.7 However, BP beyond the proposed 
limits could be detrimental due to higher risk of post-reperfu-
sion hemorrhages after EVT.8 Oscillations in systolic blood pres-
sure (SBP) after EVT may also be associated with poorer out-
comes.9 Earlier studies suggested U-shaped associations be-
tween on-admission BP and favorable clinical outcomes in 
ischemic stroke patients, but also poorer outcomes in patients 
with generally higher BP throughout hospitalizations.10-12 One 
recent analysis reported an association between higher maxi-
mum in-procedure SBP and poor 30-day outcomes, while sev-
eral others suggested the opposite—associations between 
poorer outcomes and indicators of BP dips.13-16 Thus, we hy-
pothesized that during EVT it would be reasonable to target in-
dividualized BP values. We therefore investigated the relation-
ship between in-procedure SBP and mean arterial pressure 
(MAP) excursions to above or below the limits defined in re-
spect to their pre-procedure values and (1) post-procedure im-
aging findings: ischemic lesion volume (ILV) and visible hemor-
rhages; (2) 3-month functional outcomes; in a cohort of adults 
with anterior circulation ischemic stroke treated with EVT.
Methods
Design
This is a retrospective analysis of a single-center prospective 
database comprising adults (age ≥18 years) with a symptomat-
ic acute ischemic stroke due to occlusion of the internal carot-
id artery and/or middle cerebral artery treated with EVT using 
modern stent retrievers (a few patients received thrombus as-
piration only) over a 5-year period (January 1, 2012 to Decem-
ber 31, 2016). It was approved by the Ethics Committee of 
Bundesland Salzburg. Figure 1A depicts the flow: patients un-
derwent EVT under general anesthesia (GA) with or without in-
travenous rtPA, which individually required measures for BP 
reduction;4 the analysis was restricted to patients with invasive 
BP measurement; serial BP values taken immediately before 
the start of EVT/induction of anesthesia were considered a 
“reference BP” for the period of the procedure; patients under-
went post-procedure computed tomography (CT) imaging to 
assess hemorrhages and ILV, and were evaluated for the func-
tional outcome at 3 months post-stroke (modified Rankin Scale 
Figure 1. (A) Patient flow. (B) Steps in data analysis. We analyzed relationships between blood pressure (BP) during endovascular thrombectomy (EVT) with or 
without recombinant tissue plasminogen activator (rtPA) with (1) post-procedure computed tomography (CT) findings: ischemic lesion volume (ILV) and visible 
hemorrhages; (2) functional outcome at 3 months. We explored a possibility of a mediated association: in-procedure BP → ILV/visible hemorrhage → 
3-month functional outcome.
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[mRS]). We explored the associations between in-procedure BP 
oscillations defined in relative terms versus the “reference val-
ue” and (1) post-procedure ILV and visible hemorrhages; (2) fa-
vorable 3-month functional outcome (mRS 0-2) (Figure 1B).
Clinical evaluations
Stroke severity was assessed using the National Institutes of 
Health Stroke Scale (NIHSS). Indication for EVT was made in 
line with continuously updated standards, while indication for 
rtPA was in accordance with the Safe Implementation of 
Thrombolysis in Stroke-Monitoring Study.2,17 At discharge, 
stroke etiology was classified according to the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) criteria.18 Functional 
outcome at 3 months was assessed at scheduled visits or by a 
telephone interview with the patient or a proxy.
Radiological evaluations 
CT or magnetic resonance was used to identify the vessel(s) 
portions occluded and to evaluate leptomeningeal collaterals 
on CT-angiography. Collaterals were graded as good when 
≥50% were present as compared to the unaffected side. Post-
procedure CT was used to evaluate presence of hemorrhages 
and last available CT during the index hospitalization to deter-
mine ILV.19 The reperfusion success was graded by the Throm-
bolysis in Cerebral Infarction (TICI) scale: grades 2b (perfusion 
>50% of the vascular distribution of the occluded artery) and 
3 (full perfusion with filling of all distal branches) were consid-
ered a success, grades 0-2a were considered a failure.20 
BP measurements and management
During EVT, BP was measured invasively every minute (except 
in two patients: every 2 or 5 minutes) and recordings were 
saved by the MetaVisionⓇ software (iMDsoft, Düsseldorf, Ger-
many). Otherwise, it was measured regularly (cuff technique) 
and recorded in the patient charts. The in-house algorithm for 
acute stroke patients has been constantly in agreement with 
the respective guidelines, particularly in respect to the use of 
rtPA and EVT.
BP indicators
We determined the following BP indicators: (1) “reference” 
SBP/MAP as the mean of 3 to 5 measurements taken immedi-
ately before the start of EVT (induction of anesthesia); (2) indi-
vidual values ±20% of the reference were determined and 
number of in-procedure excursions to values >120% or to 
<80% of the reference was counted to calculate their rates 
(episodes/10 minutes); (3) weighted mean in-procedure SBP/
MAP by dividing area under the curve of BP over time (first to 
last in-procedure measurement) by the time period covered. 
We also determined rates of any excursions exceeding ±20% 
of the reference, and absolute (by linear interpolation) and rel-
ative (percent) time of the procedure with SBP/MAP >120% or 
<80% of the reference values.
Data analysis
We first evaluated associations of in-procedure BP with post-
procedure ILV and hemorrhages, and then with 3-month mRS 
0-2 (Figure 1B). General linear models were fitted to ln-trans-
formed ILV (effects are geometric mean ratio [GMR], exponents 
of coefficient obtained with logarithms) and logistic models 
were fitted to hemorrhages and mRS 0-2. We considered rates 
of excursions to >120% and to <80% of the reference (ana-
lyzed jointly due to potential off-setting effects) to be the pri-
mary indicators of BP oscillations, as they were determined di-
rectly. Analyses based on derived indicators (absolute/relative 
time) provided virtually identical results, and are not shown. 
Analyses of the rate of any excursions exceeding ±20% pro-
vided no additional information (also not shown).
Several models were fitted to each outcome starting with 
larger (“full”) models (default and selected effects [stepwise 
selection with P<0.200 to enter/stay] with sequential tests of 
interactions: excursion rates*reference BP, excursion rates*TICI 
grade, reference BP/in-procedure mean BP*TICI grade), from 
which “reduced” models (to avoid overfitting) were derived (ef-
fects of primary interest and biologically/statistically plausible 
adjustments). In the analysis of 3-month mRS, intermediate 
outcomes (ILV, hemorrhages) were introduced as adjustments 
into the “reduced” models, so model selection included a fur-
ther step to “final” models. Figure 2 outlines the model selec-
tion procedure. For details on multivariate model building and 
selection see Supplementary Methods. Mediation analysis21 
evaluated possibility that the effects of BP on the functional 
outcome were mediated “through” the effects on ILV/hemor-
rhages. We used SAS version 9.4 statistical software (SAS Inc., 
Cary, NC, USA).
Results
Patients
Of the 202 admitted patients, 20 did not undergo EVT and 18 did 
not have invasive BP monitoring. The cohort analyzed for ILV and 
hemorrhages comprised 164 patients, while 155 were analyzed 
for 3-month mRS (nine patients lacked data) (Figure 3). 
Patient characteristics are summarized in Table 1 (Supple-
mentary Table 1 for laboratory tests). Both on-admission and 
reference SBP/MAP varied greatly. Reference values appeared 
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considerably lower than on-admission values, although intra-
individual differences extended from substantial reduction to a 
substantial increase (Table 1). A total of 16 patients received 
antihypertensives between admission and EVT and two re-
ceived sympathomimetics. Procedure lasted 12 to 587 minutes 
with 13 to 230 BP measurements, and 77 (46.9%) patients re-
ceived sympathomimetics during EVT (Table 1). Overall, 38/164 
(23.2%) patients had no excursions exceeding ±20% of the 
reference SBP/MAP, 68 and 70 (41.5% and 43.6% for SBP and 
MAP, respectively) experienced exclusively excursions to 
>120%, 37 and 31 (22.6% and 18.9%) exclusively excursions 
to <80%, and 21 and 25 (12.8% and 15.2%) experienced both. 
Data are summarized in Table 1 (see also Supplementary Table 
2 and Supplementary Figure 1; for absolute/relative time 
>120% and <80% of the reference). Additional BP analysis 
(Supplementary Analysis of Blood Pressure) indicated that BP-
related procedures were guided by the intention to keep BP 
within the recommended limits, and not by the presenting 
stroke characteristics.
Relationship between in-procedure BP and ILV/
post-procedure hemorrhages
Of the 164 patients, 132 (80.5%) had good collaterals, 121 
(73.8%) achieved successful reperfusion, ILV ranged 0 to 518 cm3 
and 29 (17.7%) patients had visible hemorrhages (Table 1). Full 
models were fitted to each outcome (see Supplementary Tables 
3 and 4 for complete models). Independent variables consistently 
not associated with the outcomes were consecutively removed 
(Figure 2). Reduced models are shown in Table 2. Higher rate of 
in-procedure SBP excursions to >120% of the reference was as-
sociated with lower ILV, more so at higher reference values 
(rate*reference interaction) (Table 2). As an illustration, with ref-
erence SBP <120 mm Hg (n=62) the adjusted GMR=0.89 (inter-
quartile range [IQR], 0.74 to 1.08), with reference SBP >135 mm 
Hg (n=60), GMR=0.34 (IQR, 0.15 to 0.74). The effect of SBP ex-
cursions was consistent in patients with TICI 0-2a (n=43) and 
TICI 2b-3 (n=121) (Supplementary Table 3). SBP excursions to 
<80% of the reference were not associated with ILV. Higher ad-
mission NIHSS score and male sex were associated with higher 
ILV; TICI grade 2b-3 and good collaterals were associated with 
Figure 2. Model selection strategy. All models were fitted separately for systolic blood pressure (BP) and mean arterial pressure. TICI, Thrombolysis in Cerebral 
Infarction; EVT, endovascular thrombectomy; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale. 
Intermediate (computed tomography [CT]) outcomes Primary clinical endpoint
Types of models
FULL
Initial: default and selected independents, 
main effects, no interactions
Sequentially testing interactions:
a) rate of BP excursions*reference BP;
b) rate of excursions*TICI grade;
c) reference BP*TICI, in-procedure mean 
BP*TICI
REDUCED
Keep: a) excursion rates (primary interest);
b) biologically & statistically plausible 
other effects (default or selected, 
interactions)
FINAL
Further model reduction by nal exclusion 
of the initial default effects and 
apparently irrelevant CT ndings
Ischemic lesion volume (ILV)
•Default: rate of BP excursions to >120% 
of the reference, rate of excursions to <80%, 
reference BP, in-procedure mean BP, EVT 
duration, number of BP measurements taken, 
on-admission NIHSS score, TICI grade, 
affected vessel, collaterals ≥50% as 
unaffected side, use of antihypertensives 
before EVT
•Selected: sex
Kept effects: rate of BP excursions to 
>120%, rate of BP excursions to <80%, 
reference BP, rate to >120%*reference BP 
interaction, NIHSS score, TICI grade, 
collaterals, sex
Post-procedure visible hemorrhages
•Default: rate of BP excursions to >120% 
of the reference, rate of excursions to <80%, 
reference BP, in-procedure mean BP, EVT 
duration, number of BP measurements taken, 
on-admission NIHSS score, TICI grade, use of 
antihypertensives before EVT
•Selected: stroke etiology, history of 
coronary artery disease
Kept effects: rate of BP excursions to 
>120%, rate of BP excursions to <80%, 
reference BP, in-procedure mean BP, NIHSS 
score, TICI grade, stroke etiology, history of 
coronary artery disease
mRS at 3 months 0-2 (vs. 3-6)
•Default: rate of BP excursions to >120% 
of the reference, rate of excursions to <80%, 
reference BP, in-procedure mean BP, EVT 
duration, number of BP measurements taken, 
on-admission NIHSS score, TICI grade, 
collaterals ≥50% as unaffected side, use of 
antihypertensives before EVT
•Selected: stroke etiology, pre-/post-stroke 
statin use, age
A. Without interaction and CT outcomes 
Kept effects: rate of BP excursions to >120% 
rate of BP excursions to <80%, reference BP, 
in-procedure mean BP, NIHSS score, TICI 
grade, collaterals, stroke etiology, 
pre-/post-stroke statin use, age
B. Without interaction, with CT outcomes
As A+ILV and hemorrhages
C. With interaction, without CT outcomes
As A+rate to >120%*TICI interaction
D. With interaction and CT outcomes
As C+ILV and hemorrhages
A. Without interaction and CT outcomes
Kept effects: rate of BP excursions to >120% 
rate of BP excursions to <80%, reference BP, 
NIHSS score, TICI grade, collaterals, stroke  
etiology, pre-/post-stroke statin use, age
B. Without interaction and CT outcomes
As A+ILV 
C. With interaction, Without CT outcomes
As A+rate to >120%*TICI interaction
D. With interaction and CT outcomes
As C+ILV
Vol. 20 / No. 3 / September 2018
https://doi.org/10.5853/jos.2018.01305 http://j-stroke.org 377
lower ILV. Similar associations were observed for MAP, except for 
the excursions*reference interaction (Table 2).
In-procedure BP oscillations assessed by BP excursions were 
not associated with the post-procedure hemorrhages, higher 
reference SBP/MAP tended towards higher odds, while higher 
in-procedure mean SBP/MAP was associated with lower odds 
of hemorrhages (Table 2 and Supplementary Table 4). Higher 
in-procedure SBP/MAP was determined mainly by the higher 
reference SBP/MAP (Supplementary Analysis of Blood Pressure, 
Table F). Further analysis demonstrated that higher reference 
SBP/MAP was indirectly (via in-procedure mean) associated 
with lower odds of post-procedure hemorrhages: the indirect 
effect was practically identical in size to the direct effect (Table 
2); hence, the total effect was close to zero (Supplementary 
Analysis of Post-Procedure Hemorrhages). 
Relationship between in-procedure BP and 
3-month functional outcome
Patients with mRS 0-2 (75/155, 48.4%) appeared younger, were 
more commonly men, and less commonly suffered comorbidities 
than the patients with mRS 3-6 (Table 1). They were more fre-
quently pre-index stroke statin users, and less frequently anti-
platelets or anticoagulants users (Table 1). On-admission NIHSS 
score, prevalence of cardioemobolic/unknown etiology and of tan-
dem occlusions were lower while the use of rtPA was more com-
mon and the onset-to-EVT time was shorter in patients with mRS 
0-2 (Table 1). Average on-admission and reference SBP/MAP ap-
peared similar between the two subsets and similarly low numbers 
of patients received antihypertensives between admission and EVT. 
BP decline between admission and EVT appeared somewhat great-
er in patients with mRS 3-6 (Table 1). Weighted mean in-proce-
202 Patients with anterior circulation stroke January 1, 2012–December 31, 2016
20 EVT not done
20 Underwent EVT
11 With rtPA (61%)
7 Without rtPA (39%)
18 EVT no invasive BP measurement
•TOAST: 16 CE/unk. (89%) / 2 LAA (11%)
•Vessel: 10 MCA1 (56%), 2 MCA2 (11%),
 6 tandem occlusion (33%)
By rtPA use
By TICI reperfusion 91 2b-3
(78.5%)
13 No infarction 
(14.3%)
67 Infarction 
(73.6%)
11 Bleeding
(12.1%)
ILV cm3
21.3 (0–518)
52 mRS 0-2
(57.1%)
34 mRS 3-6
(37.4%)
5 Missing data
(5.5%)
25 0-2a
(21.6%)
1 No infarction 
(4.0%)
16 Infarction 
(64.0%)
8 Bleeding
(32.0%)
ILV cm3
154 (0–461)
4 mRS 0-2
(16.0%)
20 mRS 3-6
(80.0%)
1 Missing data
(4.0%)
30 2b-3
(62.5%)
3 No infarction 
(10.0%)
19 Infarction 
(63.3%)
8 Bleeding
(26.7%)
ILV cm3
19.5 (0–350)
13 mRS 0-2
(43.3%)
16 mRS 3-6
(53.3%)
1 Missing data
(3.3%)
18 0-2a
(37.5%)
1 No infarction 
(5.6%)
15 Infarction 
(83.3%)
2 Bleeding
(11.1%)
ILV cm3
111 (0–466)
6 mRS 0-2
(33.3%)
10 mRS 3-6
(55.6%)
2 Missing data
(11.1%)
15 TICI grade 2b-3 
(83%)
Control CT nding
1 No infarction (6%)
17 Infarction (94%)
0 Bleeding 
ILV cm3 
14.3 (0–500)
7 By mRS at 3 months
0-2 (39%)
9 3-6 (50%)
2 Missing (11%)
121 Overall TICI grade 2b-3
(73.8%)
Overall control CT nding
18 No infarction (11.0%)
117 Infarction (71.3%)
29 Bleeding (17.7%)
Overall ILV cm3
30.7 (0–518)
75 Overall by mRS at 
3 months 0-2 (45.7%)
80 3-6 (48.8%)
9 Missing (5.5%) 
By mRS at 3 months
By control CT
(24-hour post EVT for
bleedings; last
availabe for ILV)
116 With rtPA
(70.7%)
164 EVT with invasive BP measurement
•TOAST: 134 CE/unk. (81.7%) / 30 LAA (18.3%)
•Vessel: 114 MCA1 (69.5%), 14 MCA2 (8.5%),
 36 tandem occlusion (22.0%)
48 With rtPA
(29.3%)
Figure 3. Disposition of patients. EVT, endovascular thrombectomy; BP, blood pressure; TOAST, Trial of Org 10172 in Acute Stroke Treatment classification; CE, 
cardioembolic; unk., unknown etiology; LAA, large artery atherosclerosis; MCA, middle cerebral artery, segment 1, segment 2; rtPA, recombinant human tissue 
plasminogen activator; TICI, Thrombolysis in Cerebral Infarction; CT, computed tomography; ILV, ischemic lesion volume; mRS, modified Rankin Scale.
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Table 1. Patient and procedure characteristics, overall and by 3-month functional outcome* 
Characteristic All patients mRS 0–2 mRS 3–6 Missing mRS
Number 164 75 80 9
Age (yr) 74 (20–92) 67 (20–91) 79 (44–92) 74 (52–89)
Male sex 73 (44.5) 37 (49.3) 31 (38.8) 5 (55.6)
Atrial fibrillation 64 (39.0) 23 (30.7) 36 (45.0) 5 (55.6)
Previous stroke 18 (11.0) 8 (11.0) 8 (10.0) 2 (22.2)
Peripheral artery disease 11 (6.7) 4 (5.3) 7 (8.8) 0 (0)
Ischemic heart disease 35 (21.3) 9 (12.0) 25 (31.3) 1 (11.1)
Carotid stenosis ≥50% 17 (10.4) 8 (10.7) 8 (10.0) 1 (11.1)
Hypertension 106 (64.6) 41 (54.7) 59 (73.8) 6 (66.7)
Diabetes mellitus 21 (12.8) 7 (9.3) 13 (16.3) 1 (11.1)
Chronic heart failure 26 (16.2) 8 (11.0) 18 (22.8) 0 (0)
Chronic renal failure 16 (9.9) 4 (56.42) 12 (15.2) 0 (0)
Pre-admission statins 135 (82.8) 68 (90.7) 60 (75.0) 1 (87.5)
Pre-admission antiplatelets 45 (27.4) 15 (20.0) 28 (35.0) 2 (22.2)
Pre-admission anticoagulants 29 (17.7) 9 (12.0) 18 (22.5) 2 (22.2)
On-admission systolic BP (mm Hg) 150 (83–223) 150 (100–210) 154 (83–223) 148 (110–192)
On-admission MAP (mm Hg) 107 (56–174) 106 (67–143) 108 (56–174) 106 (70–135)
NIHSS at presentation 18 (3–32) 16 (3–31) 20 (3–32) 18 (7–24)
Onset to first vessel imaging (min) 189 (98–900) 181 (98–374) 208 (99–639) 165 (111–900)
TOAST: cardioembolic or unknown 134 (81.7) 54 (72.0) 72 (90.0) 8 (88.9)
rtPA used 116 (70.7) 56 (74.7) 54 (67.5) 6 (66.7)
Middle cerebral artery segment 1 114 (69.5) 52 (69.3) 55 (68.8) 7 (77.8)
Middle cerebral artery segment 2 14 (8.5) 8 (10.7) 4 (5.0) 2 (22.2)
Tandem occlusion 36 (22.0) 15 (20.0) 21 (26.3) 0 (0)
Procedure duration (min) 83 (12–587) 65 (12–202) 109 (17–587) 72 (17–188)
BP measurements/procedure (n) 83 (13–230) 66 (13–203) 108 (18–230) 73 (18–189)
BP measurements/minute 1.0 (0.2–2.4) 1.0 (0.5–2.4) 1.0 (0.2–1.6) 1.0 (1.0–1.0)
SBP reference (mm Hg) 125 (73–203) 125 (93–203) 124 (73–191) 132 (98–182)
SBP ∆ reference–admission (mm Hg) –23 (–126 to 66) –19 (–88 to 43) –28 (–126 to 66) –23 (–53 to 37)
MAP reference (mm Hg) 88 (56–136) 91 (61–136) 87 (56–134) 84 (64–123)
MAP ∆ reference–admission (mm Hg) –17 (–101 to 50) –15 (–56 to 46) –18 (–101 to 50) –22 (–55 to 21)
BP treatment admission-to-procedure
None 146 (89.0) 68 (90.7) 69 (86.3) 9 (100)
BP-lowering (urapidil, clonidine) 16 (9.8) 7 (9.3) 9 (11.3) 0 (0)
BP-increasing (sympathomimetics) 2 (1.2) 0 (0) 2 (2.5) 0 (0)
Procedure mean SBP (mm Hg) 128 (69–192) 126 (83–168) 126 (67–192) 142 (106–158)
Procedure mean MAP (mm Hg) 91 (43–125) 92 (56–117) 89 (43–125) 96 (66–112)
Rates of BP excursions vs. ref. (n/10 min)†
SBP >120% 1.09 (0–9.26) 1.21 (0–9.26) 0.93 (0–8.41) 1.63 (0–8.19)
MAP >120% 1.19 (0–9.74) 1.31 (0–8.92) 1.03 (0–9.74) 1.95 (0–8.75)
SBP <80% 0.97 (0–9.20) 1.26 (0–9.04) 0.82 (0–9.20) 0.66 (0–0.98)
MAP <80% 0.79 (0–8.91) 1.08 (0–8.91) 0.66 (0–8.22) 0.11 (0–0.11)
Inotropes during procedure 77 (46.9) 33 (44.0) 38 (47.5) 6 (66.7)
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dure SPB/MAP appeared comparable, while rates of excursions to 
>120% or to <80% of the reference appeared higher in patients 
with mRS 0-2. Similar proportions of patients received sympatho-
mimetics during EVT (Table 1). Patients with mRS 0-2 more fre-
quently had good collaterals, were more frequently successfully 
reperfused, their ILV was lower and visible hemorrhages were less 
frequent. They were less frequently post-stroke statin users, likely 
due to confounding by indication (Table 1).
Full, reduced and final models were fitted to the outcome 
(see Supplementary Table 5 for complete models). Independent 
variables consistently not associated with mRS were consecu-
tively removed (Figure 2). Final models are shown in Table 3. 
The rate of SBP/MAP excursions to <80% of the reference was 
not associated with the outcome (Table 3). When not account-
ing for ILV, higher rate of SBP/MAP excursions to >120%, TICI 
grade 2b-3, good collaterals and pre-index stroke statin use 
were associated with mRS 0-2 (Table 3, Model A). Higher on-
admission NIHSS score, cardioembolic/unknown stroke etiolo-
gy, post-index stroke statin use and older age were associated 
with lower odds of mRS 0-2 (Table 3, Model A). When ac-
counted for, higher ILV was associated with lower odds of mRS 
0-2 (Table 3, Model B). At the same time, the effects of SBP/
MAP excursions, TICI grade and of collaterals were reduced to 
include unity (Table 3, Model B). Mediation analysis (Figure 4) 
showed an indirect (via ILV) association between higher rates 
of SBP/MAP excursions to >120% and mRS 0-2 (the same was 
shown for TICI 2b-3 and good collaterals).
Several models (Supplementary Table 5) indicated an interac-
tion between the rate of SBP/MAP excursions to >120% and 
TICI grade: (1) a strong association between higher rates and 
mRS 0-2 in patients with TICI 2b-3 (n=115) and none in patients 
with TICI 0-2a (n=40) with point-estimates <1.0; (2) no associa-
tion between TICI 2b-3 and mRS 0-2 in patients with zero ex-
cursion rates, with clear-cut associations between TICI 2b-3 and 
higher odds of mRS 0-2 at rates around 1.0/10 minutes and 
higher (Supplementary Table 5, Models final C, D). We consider 
final models without the interaction (Table 3) to more generally 
describe the data than the models with this (uncertain) interac-
tion that did not indicate harms ascribable to SPB/MAP excur-
sions (for the full rationale, see Supplementary Methods).
Discussion
We found that in anterior circulation stroke patients treated 
with EVT/rtPA, in whom BP was generally kept within the rec-
ommended limits, higher in-procedure SBP/MAP was associat-
ed with a better 3-month functional outcome. The findings are 
supported by the association of higher rates of in-procedure 
SBP/MAP excursions to >120% of the reference values, and of 
higher reference BP with mRS 0-2. The fact that no such asso-
ciation was observed for (higher) in-procedure mean BP is like-
ly due to aliasing by the effects of a higher number of excur-
sions over a high(er) reference value. A stronger association 
between BP excursions and in-procedure mean BP at higher 
reference BP supports such a view. Data also suggest associa-
tions between a higher rate of SBP/MAP excursions to >120% 
and lower ILV. Higher ILV was associated with lower odds of 
mRS 0-2, and mediation analysis that differentiates effects 
identifying indirect paths21 plausible in a temporal and patho-
physiological sense disclosed its mediator role: BP excursions 
Characteristic All patients mRS 0–2 mRS 3–6 Missing mRS
Leptomeningeal collaterals
Poor (<50% as on unaffected side) 32 (19.51) 6 (8.0) 24 (30.0) 2 (22.2)
Good (≥50% as on unaffected side) 132 (80.5) 69 (92.0) 56 (70.0) 7 (77.8)
Reperfusion success (TICI class 2b–3) 121 (73.8) 65 (86.7) 50 (62.5) 6 (66.7)
Control CT
No infarction, no hemorrhage 18 (11.0) 11 (14.7) 6 (7.5) 1 (11.1)
Infarction only, no hemorrhage 117 (71.3) 53 (70.6) 56 (70.0) 8 (88.9)
Hemorrhage visible 29 (17.7) 11 (14.7) 18 (22.5) 0 (0)
Ischemic lesion volume (cm3) 30.7 (0–518) 10.9 (0–466) 102 (0–518) 9.1 (0–127)
Post-procedure statin use 110 (67.5) 43 (57.3) 62 (77.5) 5 (62.5)
Values are presented as median (interquartile range) or number (%). 
mRS, modified Rankin Scale; BP, blood pressure; MAP, mean arterial pressure; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in 
Acute Stroke Treatment classification; rtPA, recombinant human tissue plasminogen activator; SBP, systolic blood pressure; TICI, Thrombolysis in Cerebral In-
farction; CT, computed tomography. 
*mRS score: favorable (score 0 to 2) or poor (score 3 to 6); †Geometric mean ratio (interquartile range). 
Table 1. Continued
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are directly associated with lower ILV, lower ILV is directly as-
sociated with a better functional outcome, excursions affect 
functional outcome “through” the effects on ILV.
The analysis has limitations common to similar recent re-
ports on the topic13-16—it did not account for the post-proce-
dural BP; it did not test specific BP targets but evaluated spon-
taneously occurring patterns, where some, otherwise possible 
patterns, might not have occurred. Also, data on the initial in-
farct volume were not available. This leaves space for the as-
sumption that patients with a larger initial infarct volume 
might have been managed at lower BP levels (to avoid hemor-
rhagic transformation), while a less stringent BP management 
might have been in place in patients with lower volumes, thus 
spuriously “grouping” poorer outcomes and lower BP (large ini-
tial volume), and better outcomes and higher BP (smaller initial 
volume). However, all observed associations were adjusted for 
on-admission NIHSS and use of antihypertensives between ad-
mission and EVT. It is reasonable to consider that these two 
variables to a large extent subsumed the “impact” of the initial 
infarct volume: if higher on-admission NIHSS (a “proxy” for 
larger infarct volume) would “go” together with higher on-ad-
mission BP, it would be associated also with immediate use of 
antihypertensives. However, our data showed that (1) higher 
on-admission BP but not NIHSS was associated with antihy-
pertensive use; (2) BP reduction from admission to EVT (adjust-
ed for on-admission BP) was similar in patients treated and not 
treated with antihypertensives; (3) neither on-admission NIHSS 
nor the use of antihypertensives were associated with refer-
ence BP or with in-procedure mean BP. Taken together, the 
findings suggest that the observed BP patterns were likely a 
consequence of the intended management within the recom-
mended limits, and were not driven by the initial stroke severity 
(i.e., initial infarct volume). Furthermore, we consider invasive 
frequent BP recordings, inclusion of unselected patients, uni-
form anesthesia, and accounting for a number of confounders 
to be the study strengths.
Table 2. Relationship between BP/BP excursions during endovascular thrombectomy to values exceeding ±20% of the reference BP and control computed to-
mography findings
Variable
Systolic blood pressure Mean arterial pressure
GMR or OR (95% CI) P GMR or OR (95% CI) P
Ischemic lesion volume
Default independent variables†,‡
Rate of BP >120% of reference (by 1/10 min) 0.72 (0.60–0.87) <0.001 0.75 (0.63–0.90) 0.002
Rate of BP <80% of reference (by 1/10 min) 1.06 (0.91–1.25) 0.443 1.10 (0.93–1.31) 0.265
Reference BP (by 10 mm Hg) 1.01 (0.85–1.19) 0.911 0.86 (0.69–1.07) 0.181
Rate of BP excursions >120%*reference BP 0.86 (0.78–0.96) 0.006 0.95 (0.86–1.04) 0.264
On-admission NIHSS score (by 1 point) 1.06 (1.01–1.11) 0.014 1.06 (1.01–1.10) 0.021
TICI grade 2b-3 (vs. 0-2a) 0.36 (0.20–0.67) 0.001 0.36 (0.20–0.67) 0.042
Affected vessel: MCA1 vs. other 0.65 (0.36–1.17) 0.153 0.72 (0.40–1.29) 0.270
Collaterals ≥50% as unaffected side (vs. no) 0.33 (0.16–0.68) 0.002 0.33 (0.16–0.67) 0.003
Selected independent variables
Men (vs. women) 1.84 (1.07–3.17) 0.028 1.78 (1.03–3.07) 0.038
Post-procedure visible hemorrhages†,§
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.03 (0.72–1.48) 0.855 1.10 (0.82–1.50) 0.479
Rate of BP <80% of reference (by 1/10 min) 0.80 (0.58–1.11) 0.183 0.77 (0.53–1.12) 0.178
Reference BP (by 10 mm Hg) 1.48 (0.99–2.28) 0.056 1.86 (1.00–3.47) 0.051
Procedure mean BP (by 10 mm Hg) 0.65 (0.40–0.96) 0.032 0.52 (0.26–0.95) 0.034
TICI grade 2b-3 (vs. 0-2a) 0.62 (0.25–1.53) 0.298 0.61 (0.25–1.50) 0.280
Selected independent variables
Cardioembolic/unknown etiology (vs. LAA) 3.61 (0.81–28.8) 0.095 3.51 (0.64–19.4) 0.149
History of coronary heart disease 2.58 (1.04–6.42) 0.041 2.56 (1.03–6.38) 0.043
BP, blood pressure; GMR, geometric mean ratio; OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; TICI, Thrombolysis in 
Cerebral Infarction; MCA, middle cerebral artery (segment 1 or 2); LAA, large artery atherosclerosis. 
*The asterisk is a part of the interaction term; †Reduced models; ‡GMR (95% CI); §OR (95% CI).
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Present findings apparently disagree with a similar recent 
report.13 Individual in-procedure BP indicators (maximum, 
minimum, dips) were evaluated for association with 30-day 
mRS in 147 EVT-treated patients. In multivariate models (13 
independents), higher maximum SBP was associated with 
lower odds of mRS 0-2. The only other significant effect was 
admission NIHSS, while collaterals, stroke etiology, ILV were 
not considered.13 The cohort differed from ours in respect to 
anesthesia (46% GA), less common rtPA use (35.8%), fewer 
reperfusion successes (50%), lower mRS 0-2 achievement 
(17%), and fewer BP recordings (every 5 minutes).13 The ap-
parently discordant results might be due to these method-
ological and cohort differences.
Three further similar studies indirectly support the present 
findings but also oppose them in a way.14-16 All three studies 
suggest benefits of “higher” in-procedure BP, but imply this in-
directly by recognizing detrimental consequences of low(er) 
MAP, i.e., in-procedure MAP dips, which we could not confirm. 
In one study (EVT under GA), at least one episode of MAP de-
cline >40% from the baseline value was associated with 
3-month mRS 3-6, but time spent at this MAP level was not.14 
Another (smaller) analysis (EVT under GA) reported no associa-
tion between the largest in-procedure MAP decline from the 
baseline value and 3-month mRS. However, lower (vs. baseline) 
average in-procedure MAP was associated with poorer mRS, 
while higher average MAP was associated with better mRS,15 
Table 3. Relationship between BP/BP excursions during endovascular thrombectomy to values exceeding ±20% of the reference value and 3-month modified 
Rankin Scale score 0-2 (final models)
Variable
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Model A: without imaging outcomes
Default independents
Rate of BP >120% of reference (by 1/10 min) 1.33 (1.01–1.76) 0.038 1.30 (1.01–1.66) 0.029
Rate of BP <80% of reference (by 1/10 min) 0.85 (0.67–1.08) 0.174 0.85 (0.65–1.10) 0.218
Reference BP (by 10 mm Hg) 1.37 (1.06–1.77) 0.013 1.49 (1.06–2.08) 0.016
On-admission NIHSS score (by 1 point) 0.85 (0.78–0.93) <0.001 0.86 (0.80–0.94) <0.001
TICI grade 2b-3 (vs. 0-2a) 3.96 (1.34–11.7) 0.009 3.72 (1.26–11.0) 0.013
Collaterals ≥50% as unaffected side (vs. no) 4.62 (1.45–11.2) 0.007 4.71 (1.44–15.4) 0.006
Selected independents
Cardioembolic/unknown etiology (vs. LAA) 0.25 (0.07–090) 0.026 0.22 (0.06–0.84) 0.018
Pre-index stroke statin use 5.88 (1.55–22.3) 0.005 4.71 (1.27–17.5) 0.013
Post-index stroke statin use 0.32 (0.12–0.82) 0.015 0.34 (0.13–0.87) 0.020
Age (by 10 yr) 0.69 (0.50–0.96) 0.020 0.72 (0.52–0.99) 0.039
Model B: including ischemic lesion volume
Default independents
Rate of BP >120% of reference (by 1/10 min) 1.25 (0.95–1.71) 0.114 1.22 (0.95–1.61) 0.115
Rate of BP <80% of reference (by 1/10 min) 0.88 (0.69–1.11) 0.291 0.89 (0.67–1.15) 0.371
Reference BP (by 10 mm Hg) 1.33 (1.02–1.77) 0.034 1.37 (0.97–1.97) 0.071
On-admission NIHSS score (by 1 point) 0.87 (0.79–0.95) 0.002 0.88 (0.81–0.96) 0.003
TICI grade 2b-3 (vs. 0-2a) 2.73 (0.89–9.10) 0.079 2.55 (0.83–8.46) 0.101
Collaterals ≥50% as unaffected side (vs. no) 2.95 (0.88–11.2) 0.080 3.04 (0.91–11.5) 0.071
Ischemic lesion volume (by 2.718-fold) 0.65 (0.50–0.83) <0.001 0.66 (0.50–0.84) <0.001
Selected independents
Cardioembolic/unknown etiology (vs. LAA) 0.19 (0.05–0.69) 0.011 0.16 (0.04–0.62) 0.007
Pre-index stroke statin use 3.94 (1.08–16.8) 0.037 3.48 (0.97–14.8) 0.057
Post-index stroke statin use 0.34 (0.12–0.88) 0.026 0.33 (0.12–0.87) 0.025
Age (by 10 yr) 0.63 (0.43–0.87) 0.005 0.65 (0.45–0.90) 0.010
BP, blood pressure; OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; TICI, Thrombolysis in Cerebral Infarction; LAA, 
large artery atherosclerosis. 
Pikija et al.  Blood Pressure during Thrombectomy 
https://doi.org/10.5853/jos.2018.01305382 http://j-stroke.org
thus being in line with present results. Detrimental effect of 
low(er) in-procedure MAP was suggested also in EVT under 
conscious sedation—lowest in-procedure MAP <100 mm Hg 
was associated with 3-month mRS 3-6.16
Despite methodological differences between the present 
and previous reports, there is evidence of detrimental conse-
quences of low in-procedure MAP.14-16 This is in apparent dis-
agreement with the reported association between high(er) 
SBP during the first 24 hours post-EVT and poor functional 
outcomes.9,22 It seems that management of BP in anterior cir-
culation acute stroke patients undergoing EVT requires differ-
ent strategies: one focused on in-procedure targets and pre-
vention of excessive dips, the other focused on the post-pro-
cedural period targeting lower levels with a prompt manage-
ment of excessive peaks.
Figure 4. Mediation analysis: association of in-procedure systolic blood pressure (SBP) and mean arterial pressure (MAP) excursions to >120% of their refer-
ence values with 3-month modified Rankin Scale (mRS) score 0-2 is mediated through their association with the ischemic lesion volume (ILV). (A) Outline of 
associations. All associations are adjusted for all other model effects. Effects are from models analyzing ILV (Table 2) and mRS (Table 3). (B) Mediation model 
for SBP. (C) Mediation model for MAP. Higher rate of blood pressure (BP) excursions, Thrombolysis in Cerebral Infarction (TICI) scale grade 2b-3 and good col-
laterals are each directly associated with lower ILV; lower ILV is directly associated with higher odds of mRS 0-2; direct association of these predictors with 
mRS 0-2 is uncertain; each is associated with mRS 0-2 indirectly, via ILV. Effects are expressed as percent change in ILV or odds of mRS 0-2 with 95% confi-
dence interval. NIHSS, National Institute of Stroke Scale.
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Conclusions
In the EVT-treated acute anterior circulation stroke patients in 
whom BP is managed within the currently recommended lim-
its, a better functional outcome might be achieved by targeting 
in-procedure BP that exceeds the pre-procedure values by 
more than 20%.
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2018.01305.
Disclosure
The authors have no financial conflicts of interest.
References
1. National Institute of Neurological Disorders and Stroke rt-PA 
Stroke Study Group. Tissue plasminogen activator for acute 
ischemic stroke. N Engl J Med 1995;333:1581-1587. 
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, 
Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours 
after acute ischemic stroke. N Engl J Med 2008;359:1317-
1329. 
3. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lings-
ma HF, Yoo AJ, et al. A randomized trial of intraarterial treat-
ment for acute ischemic stroke. N Engl J Med 2015;372:11-20. 
4. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambaki-
dis NC, Becker K, et al. 2018 Guidelines for the early manage-
ment of patients with acute ischemic stroke: a guideline for 
healthcare professionals from the American Heart Association/
American Stroke Association. Stroke 2018;49:e46-e110. 
5. Strandgaard S. Autoregulation of cerebral blood flow in hy-
pertensive patients. The modifying influence of prolonged 
antihypertensive treatment on the tolerance to acute, drug-
induced hypotension. Circulation 1976;53:720-727. 
6. Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregula-
tion of brain circulation in severe arterial hypertension. Br 
Med J 1973;1:507-510. 
7. Dirnagl U, Pulsinelli W. Autoregulation of cerebral blood flow 
in experimental focal brain ischemia. J Cereb Blood Flow 
Metab 1990;10:327-336. 
8. Mistry EA, Mistry AM, Nakawah MO, Khattar NK, Fortuny 
EM, Cruz AS, et al. Systolic blood pressure within 24 hours 
after thrombectomy for acute ischemic stroke correlates 
with outcome. J Am Heart Assoc 2017;6:e006167. 
9. Bennett AE, Wilder MJ, McNally JS, Wold JJ, Stoddard GJ, Ma-
jersik JJ, et al. Increased blood pressure variability after endo-
vascular thrombectomy for acute stroke is associated with 
worse clinical outcome. J Neurointerv Surg 2018;10:823-827. 
10. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. 
Blood pressure decrease during the acute phase of ischemic 
stroke is associated with brain injury and poor stroke out-
come. Stroke 2004;35:520-526. 
11. Grabska K, Niewada M, Sarzyńska-Długosz I, Kamiński B, 
Członkowska A. Pulse pressure: independent predictor of 
poor early outcome and mortality following ischemic stroke. 
Cerebrovasc Dis 2009;27:187-192. 
12. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA; IST Col-
laborative Group. Blood pressure and clinical outcomes in 
the International Stroke Trial. Stroke 2002;33:1315-1320. 
13. John S, Hazaa W, Uchino K, Toth G, Bain M, Thebo U, et al. 
Lower intraprocedural systolic blood pressure predicts good 
outcome in patients undergoing endovascular therapy for 
acute ischemic stroke. Interv Neurol 2016;4:151-157. 
14. Löwhagen Hendén P, Rentzos A, Karlsson JE, Rosengren L, 
Sundeman H, Reinsfelt B, et al. Hypotension during endovas-
cular treatment of ischemic stroke is a risk factor for poor 
neurological outcome. Stroke 2015;46:2678-2680. 
15. Treurniet KM, Berkhemer OA, Immink RV, Lingsma HF, Ward-
van der Stam VMC, Hollmann MW, et al. A decrease in blood 
pressure is associated with unfavorable outcome in patients 
undergoing thrombectomy under general anesthesia. J Neu-
rointerv Surg 2018;10:107-111. 
16. Whalin MK, Halenda KM, Haussen DC, Rebello LC, Frankel 
MR, Gershon RY, et al. Even small decreases in blood pres-
sure during conscious sedation affect clinical outcome after 
stroke thrombectomy: an analysis of hemodynamic thresh-
olds. AJNR Am J Neuroradiol 2017;38:294-298. 
17. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke 
W, et al. Thrombolysis with alteplase for acute ischaemic 
stroke in the Safe Implementation of Thrombolysis in 
Stroke-Monitoring Study (SITS-MOST): an observational 
study. Lancet 2007;369:275-282. 
18. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, 
Gordon DL, et al. Classification of subtype of acute ischemic 
stroke. Definitions for use in a multicenter clinical trial. 
TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 
1993;24:35-41. 
19. Pikija S, Trkulja V, Mutzenbach JS, McCoy MR, Ganger P, 
Sellner J. Fibrinogen consumption is related to intracranial 
clot burden in acute ischemic stroke: a retrospective hyper-
dense artery study. J Transl Med 2016;14:250. 
20. John S, Hazaa W, Uchino K, Hussain MS. Timeline of blood 
Pikija et al.  Blood Pressure during Thrombectomy 
https://doi.org/10.5853/jos.2018.01305384 http://j-stroke.org
pressure changes after intra-arterial therapy for acute isch-
emic stroke based on recanalization status. J Neurointerv 
Surg 2017;9:455-458. 
21. Preacher KJ, Hayes AF. SPSS and SAS procedures for estimat-
ing indirect effects in simple mediation models. Behav Res 
Methods Instrum Comput 2004;36:717-731. 
22. Goyal N, Tsivgoulis G, Pandhi A, Chang JJ, Dillard K, Ishfaq 
MF, et al. Blood pressure levels post mechanical thrombecto-
my and outcomes in large vessel occlusion strokes. Neurolo-
gy 2017;89:540-547. 
Vol. 20 / No. 3 / September 2018
https://doi.org/10.5853/jos.2018.01305 http://j-stroke.org 1
Supplementary Table 1. Routine laboratory test results taken on admission or within 24 hours, overall and by mRS score at 3 months 
Variable All patients mRS 0–2 mRS 3–6 Missing mRS
Number 164 ( 75 ( 80 ( 9 (
Serum creatinine (μmol/L) 77 (16–249) 76 (40–126) 85 (16–249) 73 (50–93)
Serum glucose (mmol/L) 6.6 (4.5–15.5) 6.2 (4.5–10.3) 7.1 (5.3–15.5) 6.4 (4.8–9.7)
Total cholesterol (mmol/L) 4.1 (2.0–7.8) 4.3 (2.5–6.4) 3.7 (2.0–7.8) 4.7 (2.8–5.2)
HDL-C (mmol/L) 1.1 (0.31–2.8) 1.1 (0.47–2.4) 1.1 (0.31–2.2) 1.7 (0.80–2.3)
LDL-C (mmol/L) 2.4 (0.52–4.7) 2.8 (0.59–4.5) 2.1 (0.52–4.7) 2.2 (1.7–3.9)
Triglycerides (mmol/L) 1.17 (0.34–4.55) 1.12 (0.46–4.55) 1.23 (0.34–3.23) 1.16 (0.56–2.08)
Fibrinogen (μmol/L) 9.9 (2.9–23.1) 9.9 (3.7–17.0) 10.0 (2.9–23.1) 10.3 (7.5–11.6)
C-reactive protein (mg/L) 0.36 (0.01–9.85) 0.29 (0.01–8.65) 0.46 (0.04–9.85) 0.38 (0.07–1.79)
Red blood cells (×1012/L) 4.4 (2.8–5.7) 4.5 (3.4–5.4) 4.2 (2.8–5.7) 4.6 (3.9–5.1)
Hematocrit (%) 39.1 (24.8–52.1) 39.5 (24.9–46.4) 37.9 (24.6–52.1) 41.1 (35.4–45.6)
Platelets (×109/L) 220 (67–572) 229 (67–572) 212 (101–431) 224 (174–286)
White blood cells (×109/L) 8.1 (3.0–70.9) 8.2 (3.0–70.9) 8.4 (3.2–27.2) 7.4 (6.0–10.1)
Values are presented as median (interquartile range).
mRS, modified Rankin Scale; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol. 
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Supplementary Table 2. Absolute (minutes) and relative (%) time spent with SBP and MAP >120% or <80% of the reference value, overall and by mRS 
score at 3 months
Variable All patients mRS 0–2 mRS 3–6 Missing mRS
Number 164 ( 75 ( 80 ( 9 (
SBP >120% of reference (min) 8.6 (0–158) 8.6 (0–84) 8.6 (0–158) 7.3 (0–59)
MAP >120% of reference (min) 9.5 (0–223) 9.2 (0–127) 9.7 (0–223) 10.7 (0–63)
SBP <80% of reference (min) 8.9 (0–152) 9.0 (0–143) 8.9 (0–152) 7.6 (0–9)
MAP <80% of reference (min) 7.2 (0–160) 7.8 (0–75) 7.3 (0–160) 1 (0–1)
SBP >120% of reference (%) 10.9 (0–93) 12.1 (0–93) 9.3 (0–84) 16.3 (0–82)
MAP >120% of reference (%) 11.9 (0–97) 13.1 (0–89) 10.3 (0–97) 19.5 (0–88)
SBP <80% of reference (%) 9.6 (0–92) 12.3 (0–90) 8.2 (0–92) 6.6 (0–9.6)
MAP <80% of reference (%) 7.8 (0–89) 10.6 (0–89) 6.6 (0–82) 1 (0–1)
Values are presented as geometric mean (range).
SBP, systolic blood pressure; MAP, mean arterial pressure; mRS, modified Rankin Scale.
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Supplementary Table 3. Relationship between BP/BP excursions during EVT to values exceeding ±20% of the reference value and ischemic lesion volume 
(computed tomography scans)
Model 
Systolic blood pressure Mean arterial pressure
GMR (95% CI) P GMR (95% CI) P
Full A: no interactions
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 0.78 (0.62–0.96) 0.021 0.79 (0.66–0.93) 0.006
Rate of BP <80% of reference (by 1/10 min) 1.02 (0.83–1.26) 0.845 1.11 (0.89–1.39) 0.342
Reference BP (by 10 mm Hg) 1.00 (0.76–1.31) 0.989 0.79 (0.53–1.17) 0.242
Procedure mean BP (by 10 mm Hg)† 0.92 (0.70–1.20) 0.538 1.06 (0.71–1.57) 0.772
Procedure duration (by 10 min) 1.01 (0.95–1.08) 0.764 1.02 (0.95–1.08) 0.639
BP measurements taken (by 10) 1.07 (0.98–1.17) 0.119 1.08 (0.99–1.17) 0.098
On-admission NIHSS score (by 1 point) 1.05 (1.00–1.11) 0.037 1.05 (1.00–1.10) 0.036
TICI grade 2b-3 (vs. 0-2a) 0.46 (0.24–0.91) 0.026 0.51 (0.26–0.98) 0.044
Affected vessel: MCA1 vs. MCA2 0.71 (0.25–1.98) 0.508 0.81 (0.29–2.23) 0.677
Affected vessel: MCA1 vs. tandem occlusion 0.70 (0.34–1.42) 0.316 0.73 (0.37–1.45) 0.371
Collaterals ≥50% as unaffected side (vs. no) 0.35 (0.17–0.74) 0.006 0.37 (0.18–0.76) 0.007
Antihypertensives before EVT (vs. no) 1.41 (0.55–3.56) 0.471 1.30 (0.53–3.23) 0.565
Selected independent variables‡
Men (vs. women) 1.89 (1.08–3.32) 0.026 1.93 (1.11–3.34) 0.020
Model fit statistics (-2ResLL, AIC, BIC) 682.44, 712.44, 757.60 674.54, 704.54, 749.70
Full B: with excursion*reference interactions
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 0.73 (0.57–0.92) 0.008 0.74 (0.58–0.93) 0.011
Rate of BP <80% of reference (by 1/10 min) 1.11 (0.81–1.52) 0.500 1.16 (0.87–1.54) 0.317
Reference BP (by 10 mm Hg) 0.88 (0.66–1.16) 0.358 0.75 (0.49–1.14) 0.178
Rate of BP excursions >120%*reference BP 0.86 (0.77–0.96) 0.008 0.96 (0.87–1.06) 0.404
Rate of BP excursions <80%*reference BP 0.98 (0.92–1.04) 0.492 0.98 (0.91–1.07) 0.710
Procedure mean BP (by 10 mm Hg)† 0.99 (0.75–1.29) 0.919 1.11 (0.74–1.67) 0.616
Procedure duration (by 10 min) 1.01 (0.95–1.07) 0.800 1.01 (0.95–1.08) 0.682
BP measurements taken (by 10) 1.06 (0.97–1.16) 0.171 1.07 (0.98–1.17) 0.109
On-admission NIHSS score (by 1 point) 1.05 (1.00–1.10) 0.041 1.05 (1.00–1.10) 0.052
TICI grade 2b-3 (vs. 0-2a) 0.47 (0.24–0.92) 0.027 0.51 (0.26–0.99) 0.046
Affected vessel: MCA1 vs. MCA2 0.86 (0.31–2.40) 0.874 0.85 (0.30–2.37) 0.748
Affected vessel: MCA1 vs. tandem occlusion 0.61 (0.30–1.24) 0.170 0.73 (0.36–1.45) 0.367
Collaterals ≥50% as unaffected side (vs. no) 0.37 (0.18–0.77) 0.008 0.37 (0.18–0.76) 0.007
Antihypertensives before EVT (vs. no) 1.50 (0.60–3.76) 0.380 1.33 (0.53–3.32) 0.539
Selected independent variables‡
Men (vs. women) 1.88 (1.08–3.29) 0.026 1.91 (1.09–3.34) 0.024
Model fit statistics (-2ResLL, AIC, BIC) 693.63, 727.63, 778.58 691.64, 725.64, 776.59
Full C: with excursions*TICI interactions
Rate of BP >120% of reference*TICI grade 1.04 (0.75–1.44) 0.818 1.09 (0.81–1.48) 0.550
Rate of BP >120% at TICI 0-2a 0.71 (0.50–1.02) - 0.85 (0.63–1.15) -
Rate of BP >120% at TICI 2b-3 0.73 (0.57–0.94) - 0.77 (0.65–0.93) -
Rate of BP <80% of reference*TICI grade 0.87 (0.64–1.18) 0.365 0.87 (0.61–1.25) 0.456
Rate of BP <80% at TICI 0-2a 0.95 (0.70–1.27) - 1.00 (0.70–1.42) -
Rate of BP <80% at TICI 2b-3 1.06 (0.85–1.33) - 1.15 (0.90–1.46) -
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Model 
Systolic blood pressure Mean arterial pressure
GMR (95% CI) P GMR (95% CI) P
TICI grade 2b-3 (vs. 0-2a) 0.45 (0.23–0.90) 0.023 0.50 (0.25–0.96) 0.039
Reference BP (by 10 mm Hg) 1.01 (0.77–1.32) 0.961 0.80 (0.54–1.20) 0.284
Procedure mean BP (by 10 mm Hg)†
  (other effects were closely similar to A and B)
0.92 (0.70–1.21) 0.539 1.04 (0.70–1.55) 0.827
Model fit statistics (-2ResLL, AIC, BIC) 685.14, 719.14, 770.09 676.94, 710.94, 761.89
Full D: with BP*TICI interactions
Rate of BP >120% of reference (by 1/10 min) 0.72 (0.57–0.92) 0.009 0.79 (0.66–0.94) 0.007
Rate of BP <80% of reference (by 1/10 min) 1.00 (0.83–1.27) 0.809 1.11 (0.88–1.39) 0.372
TICI grade 2b-3 (vs. 0-2a) 0.48 (0.25–0.94) 0.033 0.51 (0.26–1.00) 0.050
Reference BP*TICI grade 0.92 (0.67–1.26) 0.619 0.91 (0.56–1.47) 0.704
Reference BP at TICI 0-2a 0.95 (0.68–1.33) - 0.75 (0.46–1.22) -
Reference BP at TICI 2b-3 1.03 (0.77–1.39) - 0.82 (0.52–1.28) -
Procedure mean*BP TICI grade 1.02 (0.66–1.58) 0.916 1.00 (0.54–1.86) 0.998
Procedure mean BP at TICI 0-2a 0.93 (0.61–1.41) - 1.05 (0.59–1.86) -
Procedure mean BP at TICI 2b-3
  (other effects were closely similar to A and B)
0.91 (0.67–1.22) - 1.05 (0.67–1.63) -
Model fit statistics (-2ResLL, AIC, BIC) 694.74, 728.74, 779.69 685.49, 719.49, 770.44
Reduced§
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 0.72 (0.60–0.87) <0.001 0.75 (0.63–0.90) 0.002
Rate of BP <80% of reference (by 1/10 min) 1.06 (0.91–1.25) 0.443 1.10 (0.93–1.31) 0.265
Reference BP (by 10 mm Hg) 1.01 (0.85–1.19) 0.911 0.86 (0.69–1.07) 0.181
Rate of BP excursions >120%*reference BP 0.86 (0.78–0.96) 0.006 0.95 (0.86–1.04) 0.264
On-admission NIHSS score (by 1 point) 1.06 (1.01–1.11) 0.014 1.06 (1.01–1.10) 0.021
TICI grade 2b-3 (vs. 0-2a) 0.36 (0.20–0.67) 0.001 0.36 (0.20–0.67) 0.042
Affected vessel: MCA1 vs. other 0.65 (0.36–1.17) 0.153 0.72 (0.40–1.29) 0.270
Collaterals ≥50% as unaffected side (vs. no) 0.33 (0.16–0.68) 0.002 0.33 (0.16–0.67) 0.003
Selected independent variables‡
Men (vs. women) 1.84 (1.07–3.17) 0.028 1.78 (1.03–3.07) 0.038
Model fit statistics (-2ResLL, AIC, BIC) 666.00, 688.00, 721.41 666.27, 688.27, 721.68
Two types of models (each separately for systolic and mean arterial pressure) were fitted: “full” (with different interaction terms) and “reduced” (effects based 
on biological and statistical plausibility). Effects are GMRs (lesion volume was ln-transformed). GMRs for the interaction terms indicate whether the BP excur-
sion effects were conditional on reference BP; or whether BP excursion effects and the effects of reference and procedure mean BP were conditional on the 
level of reperfusion (TICI grade).
BP, blood pressure; EVT, endovascular thrombectomy; GMR, geometric means ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; 
TICI, Thrombolysis in Cerebral Infarction; MCA, middle cerebral artery (segment 1 or 2); -2ResLL, 2 residual logarithmic likelihood; AIC, Akaike information cri-
terion; BIC, Bayesian information criterion. 
*The asterisk is a part of the interaction term; †Weighted mean as area under the BP-time curve divided by the time period covered; ‡By stepwise selection 
procedure (P<0.200 to enter/stay) among: age, sex, comorbidities, use of sympathomimetics during EVT, stroke etiology, time since symptom onset till the first 
vessel image, use of recombinant tissue plasminogen activator, pre-index stroke statin, antiplatelet or anticoagulant use; §Reduced model excluded interaction 
terms if no indication of moderation (for either systolic BP or mean arterial pressure), use of antihypertensives before EVT (highly insignificant and small num-
ber of treated patients), procedure mean BP (highly insignificant, determined by excursion rates, see Supplementary Analysis of Blood Pressure), procedure du-
ration and number of BP measurements taken (highly insignificant). Affected vessel was dichotomized (MCA1/other).
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Supplementary Table 4. Relationship between BP/BP excursions during EVT to values exceeding ±20% of the reference value and finding of hemorrhages on 
post-procedure computed tomography scans
Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Full A: no interactions
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.07 (0.72–1.52) 0.714 1.14 (0.82–1.57) 0.412
Rate of BP <80% of reference (by 1/10 min) 0.78 (0.55–1.06) 0.118 0.74 (0.49–1.06) 0.101
Reference BP (by 10 mm Hg) 1.56 (1.03–2.45) 0.036 2.00 (1.05–4.10) 0.034
Procedure mean BP (by 10 mm Hg)† 0.62 (0.38–0.94) 0.026 0.50 (0.24–0.94) 0.030
Procedure duration (by 10 min) 0.98 (0.67–1.08) 0.794 0.98 (0.67–1.08) 0.814
BP measurements taken (by 10) 1.05 (0.92–1.57) 0.561 1.04 (0.91–1.55) 0.585
On-admission NIHSS score (by 1 point) 1.02 (0.94–1.11) 0.629 1.02 (0.94–1.11) 0.567
TICI grade 2b-3 (vs. 0-2a) 0.76 (0.28–2.10) 0.590 0.74 (0.28–2.04) 0.560
Use of rtPA (vs. no) 0.76 (0.29–2.04) 0.572 0.78 (0.30–2.10) 0.609
Collaterals ≥50% as unaffected side (vs. no) 0.65 (0.23–1.92) 0.425 0.61 (0.22–1.79) 0.355
Antihypertensives before EVT (vs. no) 1.52 (0.31–5.87) 0.576 1.59 (0.32–6.14) 0.539
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 4.15 (0.91–35.1) 0.068 3.94 (0.87–33.9) 0.079
History of coronary artery disease 2.40 (0.92–6.19) 0.074 2.40 (0.91–6.22) 0.075
Model fit statistics (LL, AIC, BIC) –68.059, 164.11, 207.52 –68.578, 165.15, 208.55
Full B: with excursions*reference interactions
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.27 (0.82–1.90) 0.265 1.29 (0.81–1.98) 0.265
Rate of BP <80% of reference (by 1/10 min) 0.94 (0.55–1.53) 0.821 0.97 (0.59–1.49) 0.900
Reference BP (by 10 mm Hg) 1.61 (1.04–2.59) 0.033 2.31 (1.19–4.87) 0.014
Rate of BP excursions >120%*reference BP 1.20 (0.94–1.64) 0.153 1.05 (0.87–1.32) 0.641
Rate of BP excursions <80%*reference BP 0.94 (0.84–1.04) 0.269 0.86 (0.63–1.02) 0.088
Procedure mean BP (by 10 mm Hg)† 0.56 (0.33–0.87) 0.009 0.46 (0.21–0.90) 0.023
Procedure duration (by 10 min) 0.99 (0.67–1.08) 0.868 0.99 (0.65–1.08) 0.832
BP measurements taken (by 10) 1.06 (0.92–1.59) 0.467 1.06 (0.92–1.61) 0.474
On-admission NIHSS score (by 1 point) 1.03 (0.95–1.12) 0.528 1.03 (0.95–1.12) 0.489
TICI grade 2b-3 (vs. 0-2a) 0.71 (0.26–2.03) 0.529 0.76 (0.28–2.08) 0.583
Use of rtPA (vs. no) 0.85 (0.32–2.35) 0.748 0.85 (0.33–2.34) 0.748
Collaterals ≥50% as unaffected side (vs. no) 0.75 (0.26–2.31) 0.599 0.66 (0.23–1.98) 0.444
Antihypertensives before EVT (vs. no) 1.28 (0.25–5.16) 0.745 1.66 (0.32–6.71) 0.512
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 4.82 (0.94–47.4) 0.061 5.31 (1.04–53.3) 0.045
History of coronary artery disease 2.45 (0.93–6.42) 0.059 2.70 (1.01–7.21) 0.036
Model fit statistics (LL, AIC, BIC) –66.167, 164.33, 213.93 –66.931, 165.86, 215.46
Full C: with excursions*TICI interactions
Rate of BP >120% of reference*TICI grade 1.69 (0.82–5.34) 0.170 1.41 (0.77–3.70) 0.303
Rate of BP >120% at TICI 0-2a 0.71 (0.30–1.67) - 0.84 (0.40–1.80) -
Rate of BP >120% at TICI 2b-3 1.21 (0.82–1.77) - 1.19 (0.86–1.65) -
Rate of BP <80% of reference*TICI grade 0.87 (0.54–1.41) 0.558 0.61 (0.25–1.13) 0.122
Rate of BP <80% at TICI 0-2a 0.86 (0.57–1.31) - 0.96 (0.60–1.52) -
Rate of BP <80% at TICI 2b-3 0.75 (0.51–1.11) - 0.59 (0.32–1.09) -
Pikija et al.  Blood Pressure during Thrombectomy 
https://doi.org/10.5853/jos.2018.013056 http://j-stroke.org
Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
TICI grade 2b-3 (vs. 0-2a) 0.97 (0.32–2.95) 0.958 0.89 (0.30–2.64) 0.828
Reference BP (by 10 mm Hg) 1.51 (0.99–2.40) 0.053 1.91 (0.99–3.97) 0.052
Procedure mean BP (by 10 mm Hg)†
  (other effects were closely similar to A and B)
0.63 (0.38–0.95) 0.029 0.53 (0.25–0.99) 0.048
Model fit statistics (LL, AIC, BIC) –66.756, 165.51, 215.11 –66.285, 164.56, 214.17
Full D: with BP*TICI interactions
Rate of BP >120% of reference (by 1/10 min) 1.06 (0.71–1.51) 0.763 1.09 (0.78–1.52) 0.582
Rate of BP <80% of reference (by 1/10 min) 0.79 (0.55–1.09) 0.159 0.77 (0.49–1.11) 0.172
TICI grade 2b-3 (vs. 0-2a) 0.87 (0.31–2.45) 0.799 0.91 (0.32–2.58) 0.853
Reference BP*TICI grade 0.77 (0.45–1.26) 0.296 0.62 (0.26–1.37) 0.241
Reference BP at TICI 0-2a 1.78 (1.07–2.95) - 2.45 (1.07–5.60) -
Reference at TICI 2b-3 1.36 (0.83–2.23) - 1.53 (0.69–3.39) -
Procedure mean BP*TICI grade 1.28 (0.66–2.64) 0.465 2.20 (0.79–7.32) 0.136
Procedure mean BP at TICI 0-2a 0.55 (0.29–1.01) - 0.32 (0.12–0.87) -
Procedure mean BP at TICI 2b-3
  (other effects were closely similar to A and B)
0.70 (0.42–1.17) - 0.70 (0.32–1.54) -
Model fit statistics (LL, AIC, BIC) –67.499, 166.99, 216.60 –67.439, 166.88, 216.48
Reduced§
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.03 (0.72–1.48) 0.855 1.10 (0.82–1.50) 0.479
Rate of BP <80% of reference (by 1/10 min) 0.80 (0.58–1.11) 0.183 0.77 (0.53–1.12) 0.178
Reference BP (by 10 mm Hg) 1.48 (0.99–2.28) 0.056 1.86 (1.00–3.47) 0.051
Procedure mean BP (by 10 mm Hg)† 0.65 (0.40–0.96) 0.032 0.52 (0.26–0.95) 0.034
TICI grade 2b-3 (vs. 0-2a) 0.62 (0.25–1.53) 0.298 0.61 (0.25–1.50) 0.280
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 3.61 (0.81–28.8) 0.095 3.51 (0.64–19.4) 0.149
History of coronary heart disease 2.58 (1.04–6.42) 0.041 2.56 (1.03–6.38) 0.043
Model fit statistics (LL, AIC, BIC) –69.109, 154.22, 179.02 –69.792, 155.58, 180.38
Two types of models (each separately for systolic and mean arterial pressure) were fitted: “full” (with different interaction terms) and “reduced” (effects based 
on biological and statistical plausibility). Effects are ORs. ORs for the interaction terms indicate whether the BP excursion effects were conditional on refer-
ence BP; or whether BP excursion effects and the effects of reference and procedure mean BP were conditional on the level of reperfusion (TICI grade).
BP, blood pressure; EVT, endovascular thrombectomy; OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; TICI, Thrombol-
ysis in Cerebral Infarction; rtPA, recombinant tissue plasminogen activator; LAA, large artery atherosclerosis; LL, logarithmic likelihood; AIC, Akaike information 
criterion; BIC, Bayesian information criterion.
*The asterisk is a part of the interaction term; †Weighted mean as area under the BP-time curve divided by the time period covered; ‡By stepwise selection 
procedure (P<0.200 to enter/stay) among age, sex, comorbidities, use of sympathomimetics during EVT, stroke etiology, time since symptom onset till the first 
vessel image, type of affected vessel, pre-index stroke statin, antiplatelet or anticoagulant use; §Reduced model excluded interaction terms (no indication of 
qualitative moderation), use of antihypertensives before EVT (small number of treated patients & highly insignificant), existence of collaterals, use of rtPA, 
procedure duration and number of BP measurements taken since consistently highly insignificant.
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Supplementary Table 5. Relationship between BP/BP excursions during EVT to values exceeding ±20% of the reference value and favorable functional out-
come at 3 months (mRS, score 0-2)
Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Full A: without interactions
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.49 (1.05–2.23) 0.024 1.57 (1.12–2.35) 0.007
Rate of BP <80% of reference (by 1/10 min) 0.78 (0.54–1.07) 0.129 0.73 (0.47–1.05) 0.098
Reference BP (by 10 mm Hg) 1.63 (1.06–2.74) 0.023 2.29 (1.16–5.64) 0.014
Procedure mean BP (by 10 mm Hg)† 0.78 (0.46–1.18) 0.262 0.59 (0.23–1.17) 0.145
Procedure duration (by 10 min) 0.84 (0.41–1.05) 0.321 0.77 (0.36–1.03) 0.205
BP measurements taken (by 10) 1.10 (0.85–2.28) 0.743 1.18 (0.84–2.54) 0.610
On-admission NIHSS score (by 1 point) 0.86 (0.78–0.94) <0.001 0.87 (0.79–0.94) <0.001
TICI grade 2b-3 (vs. 0-2a) 3.14 (1.03–10.7) 0.043 2.74 (0.88–9.43) 0.082
Collaterals ≥50% as unaffected side (vs. no) 4.89 (1.48–19.1) 0.008 4.81 (1.44–18.9) 0.009
Antihypertensive before EVT (vs. no) 0.81 (0.19–3.23) 0.763 0.81 (0.19–3.27) 0.767
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.23 (0.06–0.82) 0.022 0.19 (0.04–0.72) 0.013
Pre-index stroke statin use 5.73 (1.58–25.1) 0.007 4.66 (1.27–20.5) 0.019
Post-index stroke statin use 0.30 (0.10–0.79) 0.014 0.30 (0.11–0.79) 0.015
Age (by 10 yr) 0.74 (0.51–1.04) 0.101 0.78 (0.54–1.09) 0.143
Model fit statistics (LL, AIC, BIC) –71.406, 172.81, 218.46 –70.405, 170.81, 216.46
Full B: with excursions*reference interaction
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.55 (1.01–2.47) 0.043 1.59 (1.03–2.64) 0.034
Rate of BP <80% of reference (by 1/10 min) 0.89 (0.55–1.40) 0.624 0.74 (0.44–1.15) 0.192
Reference BP (by 10 mm Hg) 1.72 (1.09–3.01) 0.017 2.30 (1.13–5.84) 0.019
Rate of BP excursions >120%*reference BP 1.00 (0.85–1.18) 0.995 1.01 (0.84–1.24) 0.948
Rate of BP excursions <80%*reference BP 0.97 (0.89–1.05) 0.409 1.00 (0.89–1.13) 0.969
Procedure mean BP (by 10 mm Hg)† 0.76 (0.44–1.17) 0.228 0.59 (0.23–1.18) 0.150
Procedure duration (by 10 min) 0.81 (0.38–1.04) 0.291 0.77 (0.36–1.04) 0.216
BP measurements taken (by 10) 1.14 (0.85–2.44) 0.672 1.18 (0.84–2.55) 0.616
On-admission NIHSS score (by 1 point) 0.86 (0.78–0.94) <0.001 0.87 (0.79–0.94) <0.001
TICI grade 2b-3 (vs. 0-2a) 3.16 (1.03–10.8) 0.043 2.73 (0.88–9.48) 0.084
Collaterals ≥50% as unaffected side (vs. no) 5.53 (1.61–23.0) 0.006 4.84 (1.43–19.4) 0.011
Antihypertensive before EVT (vs. no) 0.78 (0.18–3.15) 0.728 0.81 (0.19–3.29) 0.768
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.24 (0.06–0.85) 0.027 0.19 (0.04–0.74) 0.015
Pre-index stroke statin use 5.70 (1.59–24.4) 0.007 4.67 (1.27–20.7) 0.019
Post-index stroke statin use 0.29 (0.10–0.78) 0.003 0.30 (0.11–0.80) 0.015
Age (by 10 yr) 0.74 (0.51–1.04) 0.087 0.78 (0.54–1.09) 0.148
Model fit statistics (LL, AIC, BIC) –71.059, 176.12, 227.86 –70.402, 174.80, 226.54
Full C: with excursions*TICI interaction
Rate of BP >120% of reference*TICI grade 7.72 (1.12–53.3) 0.038 2.44 (0.84–6.63) 0.080
Rate of BP >120% at TICI 0-2a 0.27 (0.04–1.75) - 0.74 (0.28–1.99) -
Rate of BP >120% at TICI 2b-3 2.10 (1.25–3.51) - 1.81 (1.19–2.75) -
Rate of BP <80% of reference*TICI grade 1.15 (0.70–1.89) 0.589 1.06 (0.57–1.96) 0.865
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Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Rate of BP <80% at TICI 0-2a 0.71 (0.41–1.22) - 0.74 (0.39–1.40) -
Rate of BP <80% at TICI 2b-3 0.82 (0.55–1.20) - 0.78 (0.51–1.17) -
Reference BP (by 10 mm Hg) 1.62 (1.02–2.79) 0.038 2.12 (1.08–5.12) 0.028
Procedure mean BP (by 10 mm Hg)† 0.78 (0.45–1.21) 0.292 0.65 (0.26–1.28) 0.238
TICI grade 2b-3 (vs. 0-2a)
  (other effects were closely similar to A and B)
7.36 (1.15–47.1) 0.035 3.67 (0.97–13.9) 0.056
Model fit statistics (LL, AIC, BIC) –66.396, 166.79, 218.53 –67.909, 169.82, 221.56
Full D: with BP*TICI interaction
Rate of BP >120% of reference (by 1/10 min) 1.56 (1.03–2.38) 0.037 1.62 (1.08–2.41) 0.019
Rate of BP <80% of reference (by 1/10 min) 0.77 (0.53–1.11) 0.182 0.74 (0.49–1.12) 0.153
TICI grade 2b-3 (vs. 0-2a) 3.60 (1.09–11.8) 0.035 3.17 (0.93–10.8) 0.065
Reference BP*TICI grade 0.71 (0.42–1.19) 0.191 0.51 (0.21–1.21) 0.125
Reference BP at TICI 0-2a 2.16 (1.09–4.29) - 3.97 (1.29–12.3) -
Reference BP at TICI 2b-3 1.53 (0.92–2.55) - 2.02 (0.88–4.61) -
Procedure mean BP*TICI grade 1.45 (0.71–1.99) 0.310 2.76 (0.85–8.98) 0.093
Procedure mean BP at TICI 0-2a 0.57 (0.26–1.29) - 0.26 (0.07–1.01) -
Procedure mean BP at TICI 2b-3 
  (other effects were closely similar to A and B)
0.84 (0.50–1.39) - 0.72 (0.30–1.73) -
Model fit statistics (LL, AIC, BIC) –70.385, 174.77, 226.51 –68.755, 171.51, 223.25
Reduced A: no interactions, no CT findings§
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.44 (1.04–2.06) 0.026 1.38 (1.03–1.83) 0.023
Rate of BP <80% of reference (by 1/10 min) 0.78 (0.57–1.05) 0.101 0.84 (0.64–1.10) 0.193
Reference BP (by 10 mm Hg) 1.58 (1.07–2.48) 0.022 1.75 (1.00–3.07) 0.042
Procedure mean BP (by 10 mm Hg)† 0.84 (0.56–1.21) 0.360 0.80 (0.47–1.36) 0.405
On-admission NIHSS score (by 1 point) 0.86 (0.78–0.93) <0.001 0.86 (0.79–0.94) <0.001
TICI grade 2b-3 (vs. 0-2a) 4.12 (1.44–13.3) 0.008 3.85 (1.29–11.5) 0.011
Collaterals ≥50% as unaffected side (vs. no) 4.81 (1.53–17.6) 0.007 4.81 (1.43–16.1) 0.007
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.27 (0.07–0.92) 0.036 0.27 (0.07–0.97) 0.035
Pre-index stroke statin use 5.77 (1.64–24.2) 0.005 4.55 (1.24–16.7) 0.015
Post-index stroke statin use 0.29 (0.11–0.75) 0.010 0.31 (0.12–0.81) 0.013
Age (by 10 yr) 0.69 (0.49–0.94) 0.020 0.72 (0.52–0.99) 0.037
Model fit statistics (LL, AIC, BIC) –73.084, 170.17, 206.69 –70.405, 170.81, 216.46
Reduced B: no interactions, with CT findings§
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.40 (0.98–2.06) 0.059 1.31(0.96–1.80) 0.079
Rate of BP <80% of reference (by 1/10 min) 0.81 (0.57–1.11) 0.190 0.88 (0.66–1.18) 0.387
Reference BP (by 10 mm Hg) 1.56 (1.01–2.60) 0.042 1.61 (0.87–2.99) 0.111
Procedure mean BP (by 10 mm Hg)† 0.83 (0.52–1.24) 0.363 0.80 (0.44–1.44) 0.443
On-admission NIHSS score (by 1 point) 0.87 (0.79–0.95) 0.002 0.88 (0.81–0.96) 0.004
TICI grade 2b-3 (vs. 0-2a) 3.02 (0.95–10.6) 0.061 2.78 (0.86–8.97) 0.080
Collaterals ≥50% as unaffected side (vs. no) 3.12 (0.91–12.2) 0.071 3.27 (0.90–11.9) 0.061
Ischemic lesion volume (by 2.718-fold) 0.62 (0.46–0.80) <0.001 0.62 (0.47–0.82) <0.001
Post-procedure visible hemorrhages (vs. no) 1.87 (0.55–6.34) 0.314 1.88 (0.57–6.22) 0.298
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Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.18 (0.04–0.68) 0.011 0.17 (0.04–0.70) 0.009
Pre-index stroke statin use 3.62 (0.97–15.7) 0.055 3.19 (0.82–12.5) 0.082
Post-index stroke statin use 0.31 (0.11–0.82) 0.018 0.31 (0.11–0.84) 0.017
Age (by 10 yr) 0.62 (0.42–0.87) 0.005 0.72 (0.52–0.99) 0.008
Model fit statistics (LL, AIC, BIC) –66.213, 160.42, 203.03 –67.075, 162.15, 204.76
Reduced C: with interaction, no CT findings§
Default independent variables
Rate of BP >120% of reference*TICI grade 8.03 (1.19–54.3) 0.033 2.64 (0.98–7.05) 0.053
Rate of BP >120% at TICI 0-2a 0.25 (0.04–1.56) - 0.62 (0.24–1.59) -
Rate of BP >120% at TICI 2b-3 1.98 (1.24–3.17) - 1.64 (1.15–2.33) -
Rate of BP <80% of reference (by 1/10 min) 0.81 (0.59–1.11) 0.182 0.80 (0.57–1.12) 0.202
Reference BP (by 10 mm Hg) 1.54 (1.00–2.38) 0.048 1.81 (1.01–3.62) 0.046
Procedure mean BP (by 10 mm Hg)† 0.86 (0.59–1.26) 0.447 0.80 (0.45–1.43) 0.458
On-admission NIHSS score (by 1 point) 0.84 (0.76–0.92) <0.001 0.86 (0.79–0.94) <0.001
TICI grade 2b-3 (vs. 0-2a) 11.1 (1.84–66.2) 0.008 5.30 (1.49–18.8) 0.010
Collaterals ≥50% as unaffected side (vs. no) 5.07 (1.47–17.5) 0.010 5.78 (1.68–19.9) 0.005
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.28 (0.07–1.12) 0.071 0.27 (0.07–1.07) 0.062
Pre-index stroke statin use 6.26 (1.52–25.7) 0.011 4.48 (1.18–17.1) 0.028
Post-index stroke statin use 0.25 (0.09–0.69) 0.007 0.28 (0.10–0.74) 0.011
Age (by 10 yr) 0.66 (0.47–0.93) 0.018 0.67 (0.45–0.95) 0.025
Model fit statistics (LL, AIC, BIC) –68.076, 162.15, 201.72 –70.079, 166.16, 205.72
Reduced D: with interaction and CT findings§
Default independent variables
Rate of BP >120% of reference*TICI grade
‡ 7.55 (0.91–62.3) 0.061 2.51 (0.92–6.81) 0.071
Rate of BP >120% at TICI 0-2a 0.24 (0.03–1.89) - 0.61 (0.23–1.59) -
Rate of BP >120% at TICI 2b-3 1.84 (1.13–3.00) - 1.53 (1.05–2.21) -
Rate of BP <80% of reference (by 1/10 min) 0.83 (0.59–1.16) 0.272 0.83 (0.57–1.19) 0.312
Reference BP (by 10 mm Hg) 1.52 (0.90–2.53) 0.056 1.71 (0.90–3.73) 0.103
Procedure mean BP (by 10 mm Hg)† 0.86 (0.56–1.30) 0.471 0.79 (0.41–1.52) 0.485
On-admission NIHSS score (by 1 point) 0.86 (0.78–0.96) 0.005 0.88 (0.80–0.97) 0.007
TICI grade 2b-3 (vs. 0-2a) 8.21 (1.07–62.8) 0.042 3.70 (0.95–14.4) 0.059
Collaterals ≥50% as unaffected side (vs. no) 3.33 (0.90–12.3) 0.072 3.88 (1.05–14.3) 0.042
Ischemic lesion volume (by 2.718-fold) 0.63 (0.48–0.83) 0.001 0.63 (0.48–0.84) 0.001
Post-procedure visible hemorrhages (vs. no) 1.75 (0.50–6.15) 0.380 1.63 (0.48–5.54) 0.435
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.19 (0.04–0.91) 0.036 0.17 (0.04–0.77) 0.021
Pre-index stroke statin use 3.91 (0.91–16.8) 0.066 3.18 (0.79–12.9) 0.104
Post-index stroke statin use 0.25 (0.09–0.73) 0.011 0.28 (0.10–0.77) 0.013
Age (by 10 yr) 0.60 (0.41–0.86) 0.006 0.60 (0.41–0.98) 0.009
Model fit statistics (LL, AIC, BIC) –62.144, 154.29, 199.94 –64.446, 158.89, 204.54
Final A: no interactions, no CT findings
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.33 (1.01–1.76) 0.038 1.30 (1.01–1.66) 0.029
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Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Rate of BP <80% of reference (by 1/10 min) 0.85 (0.67–1.08) 0.174 0.85 (0.65–1.10) 0.218
Reference BP (by 10 mm Hg) 1.37 (1.06–1.77) 0.013 1.49 (1.06–2.08) 0.016
On-admission NIHSS score (by 1 point) 0.85 (0.78–0.93) <0.001 0.86 (0.80–0.94) <0.001
TICI grade 2b-3 (vs. 0-2a) 3.96 (1.34–11.7) 0.009 3.72 (1.26–11.0) 0.013
Collaterals ≥50% as unaffected side (vs. no) 4.62 (1.45–11.2) 0.007 4.71 (1.44–15.4) 0.006
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.25 (0.07–090) 0.026 0.22 (0.06–0.84) 0.018
Pre-index stroke statin use 5.88 (1.55–22.3) 0.005 4.71 (1.27–17.5) 0.013
Post-index stroke statin use 0.32 (0.12–0.82) 0.015 0.34 (0.13–0.87) 0.020
Age (by 10 yr) 0.69 (0.50–0.96) 0.020 0.72 (0.52–0.99) 0.039
Model fit statistics (LL, AIC, BIC) –73.504, 169.01, 202.48 –73.544, 169.09, 202.56
Final B: no interactions, with lesion volume
Default independent variables
Rate of BP >120% of reference (by 1/10 min) 1.25 (0.95–1.71) 0.114 1.22 (0.95–1.61) 0.115
Rate of BP <80% of reference (by 1/10 min) 0.88 (0.69–1.11) 0.291 0.89 (0.67–1.15) 0.371
Reference BP (by 10 mm Hg) 1.33 (1.02–1.77) 0.034 1.37 (0.97–1.97) 0.071
On-admission NIHSS score (by 1 point) 0.87 (0.79–0.95) 0.002 0.88 (0.81–0.96) 0.003
TICI grade 2b-3 (vs. 0-2a) 2.73 (0.89–9.10) 0.079 2.55 (0.83–8.46) 0.101
Collaterals ≥50% as unaffected side (vs. no) 2.95 (0.88–11.2) 0.080 3.04 (0.91–11.5) 0.071
Ischemic lesion volume (by 2.718-fold) 0.65 (0.50–0.83) <0.001 0.66 (0.50–0.84) <0.001
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.19 (0.05–0.69) 0.011 0.16 (0.04–0.62) 0.007
Pre-index stroke statin use 3.94 (1.08–16.8) 0.037 3.48 (0.97–14.8) 0.057
Post-index stroke statin use 0.34 (0.12–0.88) 0.026 0.33 (0.12–0.87) 0.025
Age (by 10 yr) 0.63 (0.43–0.87) 0.005 0.65 (0.45–0.90) 0.010
Model fit statistics (LL, AIC, BIC) –67.354, 158.71, 195.23 –67.863, 159.73, 196.25
Final C: with interaction, no CT findings
Default independent variables
Rate of BP >120% of reference*TICI grade 8.42 (1.25–56.9) 0.029 2.80 (1.05–7.43) 0.039
Rate of BP >120% at TICI 0-2a 0.22 (0.04–1.35) - 0.55 (0.23–1.36) -
Rate of BP >120% at TICI 2b-3 1.84 (1.20–2.82) - 1.55 (1.12–2.14) -
TICI grade 2b-3 (vs. 0-2a) at 0 rate 1.01 (0.25–3.97) - 1.33 (0.35–5.10) -
TICI grade 2b-3 (vs. 0-2a) at 0.5/10 min 2.92 (0.92–9.27) - 2.23 (0.71–7.03) -
TICI grade 2b-3 (vs. 0-2a) at 1.0/min 8.48 (1.69–42.6) - 3.73 (1.19–11.7) -
TICI grade 2b-3 (vs. 0-2a) at mean rate 11.1 (1.84–66.2) 0.009 5.37 (1.52–18.9) 0.009
Rate of BP <80% of reference (by 1/10 min) 0.87 (0.69–1.11) 0.257 0.87 (0.67–1.12) 0.285
Reference BP (by 10 mm Hg) 1.36 (1.04–1.78) 0.026 1.50 (1.06–2.12) 0.022
On-admission NIHSS score (by 1 point) 0.84 (0.76–0.92) <0.001 0.86 (0.78–0.93) <0.001
Collaterals ≥50% as unaffected side (vs. no) 5.07 (1.47–17.5) 0.010 5.68 (1.67–19.4) 0.009
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.28 (0.07–1.12) 0.072 0.26 (0.06–1.03) 0.054
Pre-index stroke statin use 6.26 (1.52–25.7) 0.011 4.66 (1.22–17.8) 0.025
Post-index stroke statin use 0.25 (0.09–0.69) 0.007 0.29 (0.11–0.78) 0.014
Age (by 10 yr) 0.66 (0.47–0.93) 0.017 0.67 (0.48–0.95) 0.025
Model fit statistics (LL, AIC, BIC) –68.374, 160.75, 197.27 –70.370, 164.74, 201.26
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Model
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Final D: with interaction, with lesion volume
Default independent variables
Rate of BP >120% of reference*TICI grade 7.86 (0.99–62.1) 0.051 2.73 (1.02–7.31) 0.046
Rate of BP >120% at TICI 0-2a 0.21 (0.03–1.55) - 0.53 (0.21–1.31) -
Rate of BP >120% at TICI 2b-3 1.67 (1.08–2.60) - 1.43 (1.03–2.01) -
TICI grade 2b-3 (vs. 0-2a) at 0 rate 0.77 (0.18–3.20) - 0.94 (0.23–3.83) -
TICI grade 2b-3 (vs. 0-2a) at 0.5/10 min 2.16 (0.62–7.56) - 1.55 (0.46–5.24) -
TICI grade 2b-3 (vs. 0-2a) at 1.0/min 6.05 (0.99–36.6) - 2.56 (0.76–8.64) -
TICI grade 2b-3 (vs. 0-2a) at mean rate 7.21 (1.29–59.1) 0.021 3.64 (0.96–13.8) 0.057
Rate of BP <80% of reference (by 1/10 min) 0.89 (0.69–1.13) 0.341 0.89 (0.68–1.15) 0.389
Reference BP (by 10 mm Hg) 1.33 (1.01–1.79) 0.040 1.39 (0.98–2.02) 0.067
On-admission NIHSS score (by 1 point) 0.86 (0.77–0.95) 0.002 0.88 (0.80–0.96) 0.004
Collaterals ≥50% as unaffected side (vs. no) 3.35 (0.97–13.2) 0.056 3.81 (1.11–14.9) 0.033
Ischemic lesion volume (by 2.718-fold) 0.66 (0.51–0.85) 0.001 0.66 (0.51–0.85) 0.001
Selected independent variables‡
Cardioembolic/unknown etiology (vs. LAA) 0.22 (0.05–0.85) 0.028 0.19 (0.04–0.85) 0.015
Pre-index stroke statin use 4.28 (1.08–19.6) 0.038 3.44 (0.92–15.1) 0.068
Post-index stroke statin use 0.27 (0.09–0.74) 0.010 0.29 (0.10–0.78) 0.013
Age (by 10 yr) 0.61 (0.41–0.86) 0.004 0.61 (0.41–0.87) 0.005
Model fit statistics (LL, AIC, BIC) –62.945, 151.89, 191.45 –65.136, 156.27, 195.83
Three types of models (each separately for systolic and mean arterial pressure) were fitted: “full” (with different interaction terms), “reduced” and “final” (based 
on biological and statistical plausibility). Intermediate radiological outcomes were introduced to “reduced models”. Effects are ORs. ORs for the interaction 
terms indicate whether the BP excursion effects were conditional on reference BP; or whether BP excursion effects and the effects of reference and procedure 
mean BP were conditional on the level of reperfusion (TICI grade).
BP, blood pressure; EVT, endovascular thrombectomy; mRS, modified Rankin Scale; OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health 
Stroke Scale; TICI, Thrombolysis in Cerebral Infarction; LAA, large artery atherosclerosis; LL, logarithmic likelihood; AIC, Akaike information criterion; BIC, 
Bayesian information criterion; CT, computed tomography. 
*The asterisk is a part of the interaction term; †Weighted mean as area under the blood pressure-time curve divided by the time period covered; ‡By stepwise 
selection procedure (P<0.200 to enter/stay) among: age, sex, comorbidities (hypertension, atrial fibrillation, any form of occlusive arterial disease, diabetes, 
heart or renal failure), stroke etiology, type of the affected vessel, use of recombinant tissue plasminogen activator, time elapsed since symptom onset till first 
vessel image, pre- and post-index stroke use of statins, use of sympathomimetics during EVT; §Reduced models excluded interaction terms not indicative of 
qualitative moderation, use of antihypertensives before EVT (small number of treated patients & highly insignificant), procedure duration and number of BP 
measurements taken (consistently highly insignificant). Final models further excluded procedure mean BP (highly insignificant, determined by excursion rates, 
see Supplementary Analysis of Blood Pressure) and presence of post-procedure hemorrhages (consistently highly insignificant).
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Supplementary Figure 1. Rates of blood pressure excursions during endovascular procedure to >120% or to <80% of the reference. Patients are classified 
by the rate of episodes (n/10 minutes) to <80% as those with none, up to 1 and >1 episode/10 minutes, while actual rates are given on the y-axis: rates to 
>120% of the reference (upper panel) and to <80% of the reference (lower panel). Dots are individual data, shaded bars illustrate frequency of rates and 
numbers are counts of patients with no excursions to >120% of the reference.
Patient categories by the rate of excursions to >120% and <80% of the reference (n/10 min)
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Supplementary Methods
Data analysis: multivariate model building procedures
Building of all multivariate models was guided by the following general rationale: (a) indicators of in-procedure blood pressure (BP)/BP excursions from the ref-
erence value are independent variables of interest. All other potential independent variables serve to improve the control of confounding; (b) the sample size is 
rather limited, so models can sustain a limited number of independent variables; (c) selection of adjustments needs to follow (i) the nature of the independent 
variables of interest—they might be affected by procedure duration (i.e., have a “time component”), as well as by the number of measurements taken. BP excur-
sions are defined in respect to reference values; hence, may be influenced by them; (ii) (patho)physiological rationale—certain factors, e.g., stroke severity at pre-
sentation (National Institutes of Health Stroke Scale [NIHSS] score), affected vessel(s), existence of leptomeningeal collaterals, use of pharmacological fibrinoly-
sis (recombinant tissue plasminogen activator [rtPA]), the level of achieved reperfusion (Thrombolysis in Cerebral Infarction [TICI] grade [TICI 2b-3=success; TICI 
0-2a=failure]) may or are known to reflect on the control computed tomography findings (ischemic lesion volume [ILV], visible hemorrhages) and/or the 
3-month functional outcome (modified Rankin Scale [mRS] score 0-2=favorable vs. 3-6=poor); hence, should be accounted for in the analysis of the respective 
outcomes; (iii) statistical significance—within the sample, some patient characteristics might be a source of confounding although without any obvious biologi-
cal rationale and should be accounted for simply based on statistical significance; (d) consequently, all models need to include some adjustments by default, 
while others may be selected based on statistical significance; (e) some interactions need to be evaluated: is the potential effect of BP excursions from the ref-
erence value conditional on the reference value?; is it conditional on the level of reperfusion (TICI grade)?; is the potential effect of the reference or in-procedure 
BP conditional on the level of reperfusion?; (f) there is a risk of overfitting; hence, models should be selected based on biological and statistical plausibility.
The logic and algorithm of model selection is depicted in Figure A. For all outcomes, i.e., imaging (intermediate) (ILV, post-procedure hemorrhages) and the 
primary clinical endpoint (mRS score 0-2), the procedure started by fitting “full” models including a range of default and selected variables. The initial model 
contained only main effects and further models sequentially tested interactions of interest. In the next step, models were “reduced” to keep independent vari-
ables of interest and biologically and statistically plausible covariates required to demonstrate hypothesized independent associations or lack of such associa-
tions. Imaging outcomes were considered as independent variables in the analysis of the 3-month mRS, but were not included in the full models; they were 
introduced to “reduced” models. Hence, model selection in the analysis of the primary clinical endpoint included a further step of selecting the “final” models.
All full models included the following same “base” default independent variables: rate of excursions to >120% and to <80% of the reference BP, reference 
BP, weighted mean in-procedure BP, procedure duration (may also be a “proxy” of a more severe stroke/larger occlusion), number of in-procedure BP mea-
surements, reperfusion success (TICI grade 2b-3 or 0-2a), existence of leptomeningeal collaterals ≥50% as on the unaffected side, on-admission NIHSS score 
and whether antihypertensive treatment was administered between admission and endovascular thrombectomy (EVT). Since data on the initial infarct volume 
were not available, we considered that on-admission NIHSS could be reasonably considered an independent that largely included (subsumed) the impact of 
the initial volume. We included also the use of antihypertensives between admission and EVT based on the following reasoning: decision to administer antihy-
pertensives and subsequent (during EVT) decision to keep BP at lower levels/prevent excursions to higher values might have been guided by a larger (initial) 
infarct volume in order to prevent hemorrhagic transformation, and hence a spurious association between “better outcomes” (ILV, hemorrhages, 3-month 
functional outcome) and higher in-procedure BP, or “poorer outcomes” and lower in-procedure BP could be inferred. Therefore, on-admission NIHSS and use 
of antihypertensives between admission and EVT served as a kind of “proxy” to subsume the initial volume effects. A separate detailed analysis of on-admis-
sion BP, use of antihypertensives before EVT, use of sympathomimetics during EVT, weighted mean in-procedure BP and BP excursions was also performed 
(Supplementary Analysis of Blood Pressure).
In the analysis of the ILV, default adjustments additionally included the type of the affected vessel (middle cerebral artery segment 1 or segment 2, or in-
volvement of internal carotid artery, i.e., tandem occlusion), while in the analysis of the presence of visible hemorrhages this was replaced with the use of rtPA 
as it seemed more plausible to account for a known risk factor for intracerebral hemorrhage. Only “base” default independent variables were included in the 
full models analyzing the 3-month functional outcome (probability of mRS 0-2 [vs. 3-6]).
In all full models, considered for inclusion through a stepwise selection procedure (P<0.200 to enter/stay) were: age, sex, comorbidities (hypertension, atrial 
fibrillation, any form of occlusive arterial disease, diabetes, heart or renal failure), stroke etiology by Trial of Org 10172 in Acute Stroke Treatment (TOAST) clas-
sification (dichotomized as cardioembolic or unknown vs. large artery atherosclerosis), time elapsed since symptom onset till the first vessel image, type of the 
affected vessel (if not by default), use of rtPA (if not by default), use of sympathomimetics during EVT and pre-index stroke statin use. In the analysis of ILV 
and visible hemorrhages considered were also pre-index stroke use of antiplatelets and anticoagulants, while in the analysis of the 3-month functional out-
come post-procedure use of statins was considered instead.
Analysis of the 3-month functional outcome indicated a statistically significant interaction between the rate of BP excursions to >120% of the reference 
and TICI grade achieved (Figure A), suggesting no association between excursions and the outcome in patients with TICI grade 0-2a and a strong association 
of a higher rate with higher odds of mRS 0-2 in patients with TICI grade 2b-3 (Supplementary Table 5). Conversely, it indicated no association between TICI 
2b-3 and mRS 0-2 in patients with no BP excursions to >120% of the reference, and increasingly stronger association with higher odds of mRS 0-2 with the 
increasing rate of excursions (Supplementary Table 5, Model final C, D). However, since there were only 40 patients with TICI 0-2a, only 10 of whom achieved 
mRS 0-2, there is some uncertainty about this interaction. Therefore, two types of “final” models were generated (Figure A): not accounting and accounting 
for this interaction. We consider that models without the interaction generally better describe the data due to the mentioned uncertainty and: (a) lack of indi-
cation that systolic blood pressure (SBP)/mean arterial pressure (MAP) excursions in the subset of patients with TICI 0-2a were harmful—similar proportions of 
those with mRS 0-2 (4/10, 40% for SBP, 20% for MAP) and those with mRS 3-6 (20/30, 33.3% for SBP, 20% for MAP) had zero BP excursion rates to >120% 
of the reference; (b) higher reference SBP/MAP was consistently associated with higher odds of mRS 0-2, both in patients with TICI 0-2a and with TICI 2b-3 
(Supplementary Table 5); (c) at the start of EVT, TICI outcome is unknown. Present data indicate a potential benefit of higher rates of SBP/MAP excursions to 
>120% and, at worst, no benefit (but no harm); (d) differences in formal statistical indicators of model fits (Bayesian information criterion [BIC]) between the 
final models without and with the interaction term were minor (Supplementary Table 5, Models final A and B vs. C and D). Finally, each of these models was 
fitted without and with an account for ILV (Figure A). Namely, higher ILV was consistently associated with lower odds of mRS 0-2 in the “reduced” and “final” 
models (Supplementary Table 5), but introduction of ILV had another consequence: strength of association between mRS 0-2 and several independent vari-
ables (BP excursion rates to >120%, existence of good collaterals, TICI grade, pre-index stroke statin use) was considerably reduced or the association was no 
more apparent (Supplementary Table 5). This phenomenon is typical for “mediator” variables and a possibility of mediated (via ILV) associations between BP 
excursion rates, existence of collaterals and TICI grade and 3-month mRS 0-2 appeared plausible: all these variables were also independently associated with 
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ILV (Supplementary Table 3). Mediation analysis was performed specifically to test the hypothesis of an indirect association between in-procedure BP excur-
sions to >120% of the reference and the 3-month functional outcome via ILV (BP excursions → ILV → 3-month mRS) with adjustments included in the “re-
duced” model analyzing ILV and “final” (without interactions) model analyzing mRS 0-2.
Figure A. Schematic representation of the model selection strategy. All models were fitted separately for systolic blood pressure and mean arterial pressure. 
mRS, modified Rankin Scale; BP, blood pressure; TICI, Thrombolysis in Cerebral Infarction; EVT, endovascular thrombectomy; NIHSS, National Institutes of 
Health Stroke Scale; rtPA, recombinant tissue plasminogen activator.
Intermediate (computed tomography [CT]) outcomes Primary clinical endpoint
Types of models
FULL
Initial: default and selected independents, 
main effects, no interactions
Sequentially testing interactions:
a) rate of BP excursions*reference BP;
b) rate of excursions*TICI grade;
c) reference BP*TICI, in-procedure mean 
BP*TICI
REDUCED
Keep: a) excursion rates (primary interest);
b) biologically & statistically plausible 
other effects (default or selected, 
interactions)
FINAL
Further model reduction by nal exclusion 
of the initial default effects and 
apparently irrelevant CT ndings
Ischemic lesion volume (ILV)
•Default: rate of BP excursions to >120% 
of the reference, rate of excursions to <80%, 
reference BP, in-procedure mean BP, EVT 
duration, number of BP measurements taken, 
on-admission NIHSS score, TICI grade, 
affected vessel, collaterals ≥50% as 
unaffected side, use of antihypertensives 
before EVT
•Selected: sex
Kept effects: rate of BP excursions to 
>120%, rate of BP excursions to <80%, 
reference BP, rate to >120%*reference BP 
interaction, NIHSS score, TICI grade, 
collaterals, sex
Post-procedure visible hemorrhages
•Default: rate of BP excursions to >120% 
of the reference, rate of excursions to <80%, 
reference BP, in-procedure mean BP, EVT 
duration, number of BP measurements taken, 
on-admission NIHSS score, TICI grade, use of 
antihypertensives before EVT
•Selected: stroke etiology, history of 
coronary artery disease
Kept effects: rate of BP excursions to 
>120%, rate of BP excursions to <80%, 
reference BP, in-procedure mean BP, NIHSS 
score, TICI grade, stroke etiology, history of 
coronary artery disease
mRS at 3 months 0-2 (vs. 3-6)
•Default: rate of BP excursions to >120% 
of the reference, rate of excursions to <80%, 
reference BP, in-procedure mean BP, EVT 
duration, number of BP measurements taken, 
on-admission NIHSS score, TICI grade, 
collaterals ≥50% as unaffected side, use of 
antihypertensives before EVT
•Selected: stroke etiology, pre-/post-stroke 
statin use, age
A. Without interaction and CT outcomes 
Kept effects: rate of BP excursions to >120% 
rate of BP excursions to <80%, reference BP, 
in-procedure mean BP, NIHSS score, TICI 
grade, collaterals, stroke etiology, 
pre-/post-stroke statin use, age
B. Without interaction, with CT outcomes
As A+ILV and hemorrhages
C. With interaction, without CT outcomes
As A+rate to >120%*TICI interaction
D. With interaction and CT outcomes
As C+ILV and hemorrhages
A. Without interaction and CT outcomes
Kept effects: rate of BP excursions to >120% 
rate of BP excursions to <80%, reference BP, 
NIHSS score, TICI grade, collaterals, stroke  
etiology, pre-/post-stroke statin use, age
B. Without interaction and CT outcomes
As A+ILV 
C. With interaction, Without CT outcomes
As A+rate to >120%*TICI interaction
D. With interaction and CT outcomes
As C+ILV
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Supplementary Analysis of Blood Pressure
Relationship between on-admission blood pressure (BP), BP at the start of endovascular thrombectomy 
(EVT), use of BP-related treatments between admission and EVT, use of sympathomimetics during EVT, 
weighted mean BP during EVT and rate of BP oscillations
Most subjects received no BP-related treatment between admission and EVT (n=146), two subjects received sympathomimetics and 16 received BP-lowering 
treatment (15 received 5 to 75 mg of urapidil intravenously, 1 received 50 mg urapidil+0.075 mg clonidine subcutaneously). The latter subset was character-
ized by numerically higher on-admission systolic blood pressure (SBP) and mean arterial pressure (MAP) and a greater average within-subject decline in SBP 
and MAP between admission and EVT (reference BP values appeared comparable across subsets) (Table A). Similar proportions of subjects received sympatho-
mimetics during EVT (Table A).
We undertook the following analyses: 
1. Identification of on-admission characteristics associated with the use of antihypertensives between admission and EVT
2. Identification of factors associated with the extent of blood pressure change between admission and start of EVT
3. Relationship between on-admission BP and BP at the start of EVT (“reference BP”)
4. I dentification of on-admission characteristics and factors occurring between admission and EVT associated with the use of sympathomimetics during EVT
5. Identification of factors associated with weighted mean BP during EVT and BP excursions to >120% or <80% of the reference BP during EVT
1. On-admission characteristics associated with the use of antihypertensives between admission and EVT
The use of antihypertensive treatment between admission and start of EVT was considered a binary dependent variable (the two patients who received sym-
pathomimetics were considered as “not treated with antihypertensives”), and was analyzed in a logistic model. It included three default independent variables: 
on-admission SBP, on-admission MAP, and clinical stroke severity on admission (National Institutes of Health Stroke Scale [NIHSS] score). Demographics, 
medical history, comorbidity, type of affected vessel (dichotomized as middle cerebral artery segment 1 vs. other) and whether recombinant tissue plasmino-
gen activator (rtPA) was used along EVT were considered as potential independent variables through a stepwise selection procedure with P<0.200 to enter/
stay in the model. Results are summarized in Table B. Higher on-admission SBP was associated with higher odds of being administered antihypertensives, 
while pre-stroke anticoagulant use and middle cerebral artery segment 1 occlusion were associated with lower odds. MAP and stroke severity at presentation 
did not appear associated with the odds of administration of antihypertensives between admission and EVT. 
2. Factors associated with the extent of BP change between admission and start of EVT
The extent of intra-individual BP change between admission and start of EVT (∆ reference – on-admission BP) was considered a dependent variable, separate-
ly for SBP and MAP. Two models were fitted—Model 1 did not include on-admission BP value, while Model 2 included this adjustment as well. Model 1 in-
cluded two default independent variables—age and antihypertensive treatment; Model 2 included three default independent variables—age, use of antihyper-
tensives and on-admission BP value. Other effects were selected through backward elimination (P<0.200) from a full model including demographic and medi-
cal history data, use of rtPA, time-lag between admission BP and reference BP measurement, affected vessel and on-admission NIHSS score. Results are sum-
marized in Table C. When not accounting for on-admission BP (Table C, Model 1), patients who received antihypertensive treatment between admission and 
start of EVT experienced a considerably greater reduction in BP (vs. those who did not): by around 26 mm Hg greater reduction in SBP and by around 15 mm 
Hg greater reduction in MAP. There appeared also a tendency towards a greater BP reduction in older subjects. However, when on-admission BP was taken 
into consideration (Table C, Model 2), the difference between antihypertensive-treated and not-treated patients was several-fold reduced and appeared minor. 
The effect of age was also reduced. By 1 mm Hg higher on-admission BP (both SBP and MAP) was associated with by close to 1 mm Hg greater BP reduction.
3. Relationship between on-admission BP and BP at the start of EVT (“reference BP”)
To evaluate the relationship between on-admission and reference BP (ln-transformed dependent variable), a model was fitted to data with on-admission NI-
HSS score, use of antihypertensives between admission and EVT and on-admission BP as independent variables. On-admission values were mean-centered (to 
avoid collinearity) since the model explored potential linear and quadratic relationship, and also included interaction terms between on-admission BP and use 
of antihypertensives to assess potential dissimilarities between on-admission and reference BP relationship in patients treated and not treated with antihy-
pertensives. Results are summarized in Table D. Figure B shows scatterplot of individual data and adjusted linear and quadratic regression lines overall and by 
subsets of patients in respect to antihypertensive treatment between admission and start of EVT (separately for SBP and MAP). Considering both SBP and 
MAP, there appeared no association between on-admission NIHSS score and reference BP, while differences between patients who received and who did not 
receive antihypertensives between admission and EVT were minor (Table D).
Regarding SBP, there was a linear association between higher on-admission and higher reference systolic BP (P=0.024) and a stronger quadratic association 
(P=0.004) (Table D). Adjusted linear regression lines are depicted in Figure BA. The interaction terms between on-admission BP and antihypertensive treatment 
were insignificant suggesting a similar relationship between on-admission and reference BP in patients not treated and treated with antihypertensives (Table 
D). In both subsets, there was a linear and a stronger quadratic association between on-admission and reference BP (Table D). Adjusted regression lines are 
depicted in Figure BB.
Regarding MAP, graphically (Figure BA), there appeared a linear and a quadratic association between on-admission BP and reference BP, but in this model 
neither appeared significant (Table D). Interaction terms between antihypertensive treatment and on-admission BP did not indicate substantial differences in 
on-admission-to-reference BP relationship in subsets of patients treated or not treated with antihypertensives between admission and EVT. Numerically, coef-
ficients were similar (Table D), but a “near-significant” linear (P=0.055) and a stronger quadratic (P=0.019) relationship was observed only in the larger subset 
of non-treated patients (Table D). Adjusted regression lines for the two subsets of patients are depicted in Figure BB.
4. Factors between admission and EVT associated with the use of sympathomimetics during EVT
Logistic model was fitted to a binary dependent variable “sympathomimetic use during EVT” with reference BP (systolic, MAP), age, admission NIHSS, use of 
rtPA, use of antihypertensives between admission and EVT, type of affected vessel and use of antihypertensives type of affected vessel interaction. Results are 
summarized in Table E.
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There appeared no association between the use of sympathomimetics during EVT and reference systolic BP or MAP, stroke severity, use of rtPA, use of anti-
hypertesives before EVT and age. Subjects suffering a middle cerebral artery (MCA) 1 stroke were less likely to receive sympathomimetics during EVT –similarly 
in patients who received and who did not receive antihpyertensives before EVT. 
5. Factors associated with weighted mean BP during EVT and BP excursions to >120% or <80% of the reference BP
General linear models were fitted to weighted mean systolic BP/MAP during EVT. Higher reference BP and higher rate of BP excursions to >120% of the refer-
ence during EVT were independently associated with higher mean SBP/MAP (Table F). The coefficient for the interaction term indicated that the “effect” of 
excursions was higher at higher reference BP (understandably). Higher rate of BP excursions to <80% was independently associated with lower mean SBP/
MAP during EVT (Table F). The interaction between the rate of excursions to <80% and reference BP was highly insignificant and was removed. Men tended 
to have lower mean BP during EVT than women (Table F). No association was observed between age, on-admission NIHSS score, pre-EVT use of antihyperten-
sives, use or rtPA, type of affected vessel, procedure duration, number of BP measurements taken and use of sympathomimetics during EVT and the mean BP 
during the procedure (Table F).
Poisson regression models were fitted to the rate of SBP/MAP excursions to >120% and to <80% of the reference BP. Higher reference SBP was indepen-
dently associated with a lower risk of SBP excursions to >120% and a higher risk of excursions to <80% (Table G). The same pattern of associations was ob-
served for reference MAP and MAP excursions during EVT (Table G). For both SBP and MAP, use of sympathomimetics during EVT tended towards association 
with a higher risk of excursions to >120% and a lower risk of excursions to <80% (Table G). Pre-EVT use of antihypertensives was associated with lower risk 
of SBP excursions to >120% and tended to a higher risk of excursions to <80% (Table G). For both SBP and MAP, rtPA use tended to association with a higher 
risk of excursions to >120 mm Hg and a lower risk of excursions to <80% (Table G).
The present analyses indicate: (a) on-admission BP appeared the main driver of a decision to administer antihypertensives before EVT, regardless of the 
stroke severity, likely in order to achieve recommended BP levels for the reperfusion procedure; (b) the predominant decline in BP between admission and start 
of EVT was only partly ascribable to administered antihypertensives since it occurred to a similar extent in patients not treated with antihypertensives, likely 
due to calming/induction of general anesthesia. It did not appear associated with the stroke severity; (c) reference BP appeared the main factor guiding the 
“tolerance” towards BP excursions during EVT (and, hence, overall weighted mean BP) independently of the means by which it was achieved (i.e., with or 
without pre-EVT antihypertensive use)—higher reference was strongly associated with a lower risk of excursions to higher values and a higher risk of excur-
sions to lower values (vs. the reference). The rate of oscillations did not appear associated with clinical stroke severity. The use of sympathomimetics during 
EVT appeared associated with BP excursions just in a way opposite to reference BP. Overall data suggest that BP-related measures (antihypertensives, sympa-
thomimetics, “tolerance” towards excursions) were guided predominantly by the intention to ascertain BP values within the recommended limits for reperfu-
sion procedures, and not by stroke characteristics. 
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Table A. Subject characteristics in respect to received blood pressure-related treatment between admission and the start of endovascular thrombectomy
Characteristic
No BP-related treatment between 
admission and EVT
BP-lowering treatment between 
admission and EVT
Sympathomimetics between ad-
mission and EVT
Number 146 16 2
Age (yr) 74 (20 to 92) 76 (53 to 90) 44 to 79
Male sex 66 (45.2) 7 (43.8) 0
Atrial fibrillation 58 (39.7) 5 (31.3) 1
History of hypertension 95 (65.1) 11 (68.8) 0
Previous stroke 17 (11.6) 0 (0) 1
Peripheral artery disease 11 (7.5) 0 (0) 0
Ischemic heart disease 31 (21.2) 3 (18.8) 1
Carotid stenosis ≥50% 15 (10.3) 2 (12.5) 0
Chronic heart failure 25 (17.5) 1 (6.3) 0
Pre-admission anticoagulants 27 (18.5) 1 (6.3) 1
Middle cerebral artery segment 1 104 (71.2) 8 (50.0) 2
Middle cerebral artery segment 2 12 (8.2) 2 (12.5) 0
Tandem occlusion 30 (20.6) 6 (37.5) 0
Admission SBP (mm Hg) 150 (83 to 220) 178 (120 to 223) 100 to 120
Admission MAP (mm Hg) 107 (56 to 167) 115 (97 to 174) 73 to 95
Admission NIHSS (score) 18 (3 to 32) 19 (9 to 32) 16 to 22
Lag: admission–reference BP (min) 24 (1 to 68) 26 (7 to 45) 25 to 52
Reference SBP (mm Hg) 125 (73 to 203) 121 (95 to 174) 116 to 139
SPB ∆ reference–admission (mm Hg) –22 (–105 to 66) –42 (–126 to 0) –4 to 39
Reference MAP (mm Hg) 89 (45 to 136) 84 (63 to 124) 83 to 100
MAP ∆ reference–admission (mm Hg) –16 (–101 to 50) –29 (–83 to 8) –12 to 27
Use of rtPA 103 (70.6) 12 (75.0) 1
Sympathomimetics during EVT 67 (45.9) 9 (56.3) 1
EVT weighted mean SBP (mm Hg) 128 (69 to 192) 125 (99 to 155) 109 to 127
EVT weighted mean MAP (mm Hg) 92 (43 to 125) 89 (67 to 106) 82 to 96
Rates of BP excursions (n/10 min)
SBP >120% of reference 1.17 (0 to 9.26) 0.72 (0 to 3.75) 0 to 0.35
MAP >120% of reference 1.18 (0 to 9.74) 1.15 (0 to 4.0) 0 to 2.62
SBP <80% of reference 0.95 (0 to 9.20) 0.83 (0 to 7.79) 0 to 7.03
MAP <80% of reference 0.75 (0 to 8.92) 0.90 (0 to 8.21) 0 to 6.2
Values are presented as median (range), geometric mean (range) for rates of BP excursions, and count (percent). Individual data are shown for two subjects 
who received sympathomimetics between admission and EVT.
BP, blood pressure; EVT, endovascular thrombectomy; SBP, systolic blood pressure; MAP, mean arterial pressure; NIHSS, National Institutes of Health Stroke 
Scale; rtPA, recombinant tissue plasminogen activator.
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Table B. Summary of multivariate analysis of the outcome “antihypertensive treatment between admission and endovascular thrombectomy”
Variable OR (95% CI) P
Default independent variables
On-admission SBP (by 10 mm Hg) 1.47 (1.01–2.22) 0.045
On-admission mean arterial pressure (by 10 mm Hg) 0.95 (0.54–1.63) 0.858
On-admission NIHSS score (by 1 score point) 1.04 (0.95–1.15) 0.405
Selected independent variables 
Pre-stroke anticoagulant use (vs. none) 0.15 (0.01–0.97) 0.045
Affected is middle cerebral artery segment 1 (vs. other) 0.35 (0.11–1.10) 0.072
OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; NIHSS, National Institutes of Health Stroke Scale. 
Table C. Summary of multivariate analysis of the outcome “change in BP between admission and start of endovascular thrombectomy”
Variable
Change in SBP Change in MAP
∆ Change (95% CI) P ∆ Change (95% CI) P
Model 1 (not accounting for admission BP)
Received antihypertensive treatment (vs. no) –25.6 (–41.6 to –9.6) 0.002 –14.5 (–25.9 to –3.0) 0.014
Age (by 10 yr) –2.6 (–6.0 to 0.7) 0.127 –2.3 (–4.7 to 0.1) 0.065
Model 2 (accounting for admission BP)
Default independent variables
Received antihypertensive treatment (vs. no) –6.1 (–18.2 to 5.9) 0.315 –2.7 (–11.3 to –5.8) 0.529
Age (by 10 yr) –1.3 (–3.9 to 1.2) 0.300 –0.4 (–2.2 to 1.4) 0.678
On-admission BP (by 1 mm Hg) –0.9 (–1.0 to –0.7) <0.001 –0.9 (–1.0 to –0.7) <0.001
Selected independent variables
Men (vs. women) - - –4.1 (–9.2 to 0.9) 0.105
Pre-existing hypertension (vs. no) - - –3.8 (–9.0 to 1.5) 0.161
BP, blood pressure; SBP, systolic blood pressure; MAP, mean arterial pressure; CI, confidence interval.  
Table D. Summary of multivariate analysis of “reference BP” (separately for systolic and mean arterial pressure)
Variable
Systolic blood pressure Mean arterial pressure
β (95% CI) P β (95% CI) P
On-admission NIHSS score (by 5 points) 0.013 (–0.009 to 0.036) 0.234 0.001 (–0.024 to 0.025) 0.920
Received antihypertensives (vs. no) 0.024 (–0.096 to 0.144) 0.697 –0.041 (–0.149 to 0.068) 0.461
On-admission BP (by 10 mm Hg) 0.026 (0.003 to 0.049) 0.024 0.021 (–0.028 to 0.070) 0.398
On-admission BP2 (by 100 mm Hg) –0.007 (–0.012 to –0.002) 0.004 –0.005 (–0.014 to 0.004) 0.280
On-admission BP*antihypertensives 0.024 (–0.021 to 0.069) 0.287 0.008 (–0.089 to 0.104) 0.870
On-admission BP2*antihypertensives –0.006 (–0.016 to 0.004) 0.208 0.002 (–0.017 to 0.021) 0.825
BP when no antihypertensive treatment 0.014 (0.003 to 0.025) 0.013 0.017 (0.000 to 0.034) 0.055
BP when antihypertensive treatment 0.038 (–0.006 to 0.082) 0.086 0.025 (–0.070 to 0.012) 0.607
BP2 when no antihypertensive treat. –0.004 (–0.007 to –0.001) 0.007 –0.006 (–0.011 to –0.001) 0.019
BP2 when antihypertensive treatment –0.011 (–0.020 to –0.001) 0.029 –0.004 (–0.022 to 0.014) 0.654
Models are fitted to ln-transformed reference BP values.
BP, blood pressure; CI, confidence interval; BP2, blood pressure by 100 mm Hg; NIHSS, National Institutes of Stroke Scale.
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Table E. Summary of multivariate analysis of the outcome “sympathomimetic use during EVT”
OR (95% CI) P
Systolic BP at start of EVT (by 10 mm Hg) 1.12 (0.83–1.53) 0.449
Mean arterial pressure at start of EVT (by 10 mm Hg) 0.83 (0.54–1.25) 0.376
Age (by 10 yr) 1.00 (0.78–1.28) 0.999
On-admission NIHSS (by 5 points) 1.14 (0.85–1.53) 0.393
Use of rtPA (vs. no) 0.72 (0.35–1.47) 0.373
Use of antihypertensive before EVT (vs. no) 1.18 (0.66–2.18) 0.577
Middle cerebral artery segment 1 (vs. other) 0.56 (0.30–0.97) 0.041
Antihypertensive use*affected vessel 0.73 (0.38–1.30) 0.293
Use of antihypertensives at MCA1 0.74 (0.14–3.34) -
Use of antihypertensives at “other vessel” 2.59 (0.59–20.1) -
MCA1 vs. “other” at antihypertensives use 0.17 (0.01–1.41) -
MCA1 vs. “other” at no antihypertensive use 0.58 (0.27–1.23) -
EVT, endovascular thrombectomy; OR, odds ratio; CI, confidence interval; BP, blood pressure; NIHSS, National Institutes of Health Stroke Scale; rtPA, recombi-
nant tissue plasminogen activator; MCA, middle cerebral artery.
Table F. Summary of multivariate analyses of weighted mean SBP and MAP during EVT
Variable
Weighted mean SBP Weighted mean MAP
β (95% CI) P β (95% CI) P
Reference BP (mm Hg) 0.76 (0.66 to 0.86) <0.001 0.80 (0.71 to 0.89) <0.001
Rate: BP >120% reference (n/10 min) 5.11 (3.99 to 6.24) <0.001 3.58 (2.87 to 4.29) <0.001
Reference BP*rate >120% 0.08 (0.02 to 0.15) 0.008 0.07 (0.03 to 0.10) <0.001
Rate: BP <80% reference (n/10 min) –4.96 (–5.91 to –4.02) <0.001 –3.48 (–4.16 to –2.80) <0.001
Age (by 10 yr) 0.21 (–1.01 to 1.42) 0.738 –0.21 (–1.01 to 0.59) 0.605
Men (vs. women) –3.41 (–6.63 to –0.18) 0.039 –1.82 (–3.97 to –0.32) 0.095
On-admission NIHSS score 0.02 (–0.27 to 0.31) 0.894 0.10 (–0.09 to 0.29) 0.293
MCA1 (vs. “other” vessel) –1.50 (–5.05 to 2.06) 0.407 –1.80 (–4.13 to 0.55) 0.133
rtPA use (vs. no) –1.87 (–5.47 to 1.74) 0.308 –0.98 (–3.40 to 1.44) 0.425
Pre-EVT antihypertensives (vs. no) 1.57 (–3.83 to 6.98) 0.566 1.44 (–2.11 to 5.01) 0.424
Sympathomimetics during EVT (vs. no) 0.31 (–2.91 to 3.53) 0.850 0.17 (–1.98 to 2.32) 0.877
EVT duration (min) –0.01 (–0.05 to 0.03) 0.541 –0.00 (–0.03 to 0.02) 0.787
BP measurements during EVT (n) –0.01 (–0.05 to 0.04) 0.813 –0.01 (–0.04 to 0.03) 0.734
SBP, systolic blood pressure; MAP, mean arterial pressure; EVT, endovascular thrombectomy; CI, confidence interval; BP, blood pressure; NIHSS, National Insti-
tutes of Health Stroke Scale; MCA, middle cerebral artery; rtPA, recombinant tissue plasminogen activator.
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Table G. Summary of multivariate analyses of the “rate (n/10 min) of BP excursions to >120% of the reference BP during EVT” and “rate of BP excursions to 
<80% of the reference BP during EVT” 
Variable
Rate to >120% Rate to <80%
RR (95% CI) P RR (95% CI) P
Model of SBP/SBP excursions
Reference BP (by 10 mm Hg) 0.66 (0.61–0.72) <0.001 1.63 (1.52–1.76) <0.001
Sympathomimetics during EVT (vs. no) 1.21 (0.89–1.62) 0.220 0.67 (0.45–0.98) 0.040
Pre-EVT use of antihypertensives (vs. no) 0.57 (0.31–0.98) 0.040 1.54 (0.82–2.76) 0.175
rtPA used (vs. no) 1.46 (1.04–2.08) 0.029 0.81 (0.52–1.26) 0.338
Age (by 10 yr) 1.10 (0.98–1.24) 0.095 0.86 (0.75–0.99) 0.036
Men (vs. women) 1.09 (0.81–1.46) 0.576 1.21 (0.81–1.81) 0.340
On-admission NIHSS (by 10 points) 0.99 (0.76–1.29) 0.965 0.77 (0.54–1.10) 0.150
MCA1 (vs. “other” vessel) 0.73 (0.53–1.03) 0.072 0.76 (0.51–1.12) 0.163
EVT duration (by 10 min) 0.95 (0.81–1.02) 0.267 0.96 (0.74–1.03) 0.433
BP measurements during EVT (by 10) 1.05 (0.97–1.25) 0.270 1.10 (0.93–1.43) 0.232
Model for MAP/MAP excursions
Reference BP (by 10 mm Hg) 0.60 (0.54–0.67) <0.001 1.97 (1.75–2.23) <0.001
Sympathomimetics during EVT (vs. no) 1.36 (1.03–1.79) 0.030 0.85 (0.56–1.28) 0.444
Pre-EVT use of antihypertensives (vs. no) 0.70 (0.40–1.14) 0.156 0.97 (0.48–1.83) 0.930
rtPA used (vs. no) 1.38 (1.02–1.90) 0.035 0.61 (0.38–0.98) 0.042
Age (by 10 yr) 1.07 (0.96–1.20) 0.199 0.93 (0.81–1.09) 0.359
Men (vs. women) 1.10 (0.84–1.44) 0.501 1.36 (0.87–2.14) 0.181
On-admission NIHSS (by 10 points) 0.92 (0.72–1.18) 0.514 1.13 (0.76–1.68) 0.551
MCA1 (vs. “other” vessel) 1.00 (0.75–1.37) 0.975 0.66 (0.43–1.01) 0.058
EVT duration (by 10 min) 0.95 (0.84–1.02) 0.232 0.95 (0.73–1.01) 0.130
BP measurements during EVT (by 10) 1.05 (0.97–1.20) 0.266 1.09 (0.93–1.41) 0.211
Four separate models were fitted: one for each rate, separately for SBP and MAP.
BP, blood pressure; EVT, endovascular thrombectomy; RR, relative risk; CI, confidence interval; SBP, systolic blood pressure; rtPA, recombinant tissue plasmino-
gen activator; NIHSS, National Institutes of Health Stroke Scale; MCA, middle cerebral artery; MAP, mean arterial pressure.
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Figure B. Relationship between on-admission blood pressure (BP) and BP at the start of endovascular thrombectomy (EVT) (reference BP: mean of 3–5 values 
at anesthesia induction). (A) Overall (all patients). Closed circles are observed individual data, lines are adjusted regression lines. (B) By subset of patients in re-
spect to administered antihypertensive treatment between admission and EVT. Symbols are observed individual data, lines are adjusted regression lines (both 
linear and quadratic). Since quadratic relationship was indicated by the initial analysis, mean-centered on-admission values were used (to avoid collinearity 
between linear and quadratic terms) in the main analysis. BP values at the beginning of EVT were ln-transformed; hence, log scale is used at the y-axis. The 
model is depicted in Table D.
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Supplementary Analysis of Post-Procedure Hemorrhages
Analysis of the relationship between blood pressure (BP)/BP excursions during endovascular thrombectomy (EVT) to values >120% or <80% of the reference 
value and finding of visible hemorrhages on the post-procedure computed tomography scans (Supplementary Table 4) demonstrated a consistent lack of as-
sociation between in-procedure BP excursions and the outcome (across a range of models). However, it disclosed an apparently counterintuitive finding: high-
er reference systolic blood pressure (SBP)/mean arterial pressure (MAP) consistently tended towards or was associated with higher odds of hemorrhages, 
whereas higher in-procedure mean BP was consistently associated lower odds of hemorrhages (Supplementary Table 4). Two observations indicated that the 
relationship between reference BP, in-procedure mean BP and hemorrhages could be a complex one:
1.  Strength of association between reference BP and hemorrhages and strength of association between in-procedure mean BP and hemorrhages appeared al-
most identical (but in an opposite direction). In the “reduced” model in Supplementary Table 4, odds ratio (OR) for the reference SBP was 1.48 and its in-
verse value (0.67) is almost identical to the OR for the procedure mean SBP (OR=0.65). The same applies for reference MAP (OR=1.86; inverse value=0.53) 
and in-procedure mean MAP (OR=0.52).
2. Supplemental analysis of BP (Table F) demonstrated that in-procedure mean BP was greatly determined by the reference BP.
We undertook the following analyses:
(a)  We re-fitted the “reduced” model in Supplementary Table 4 with (i) inclusion of an interaction term between reference BP and in-procedure mean BP; (ii) 
with exclusion of the in-procedure mean BP, while reference BP was retained; (iii) with exclusion of reference BP, while in-procedure mean BP was re-
tained.
(b)  We performed mediation analysis in which reference BP was considered a predictor, in-procedure mean was considered a mediator, presence of post-pro-
cedure hemorrhages was an outcome, while other effects from the “reduced” model in Supplementary Table 4 were covariates. All associations in the 
model, direct (predictor-mediator; mediator-outcome; predictor-outcome) and indirect (predictor-outcome, via mediator) were adjusted for all other ef-
fects; hence, all were independent.
1. Re-fitted “reduced” model from Supplementary Table 4
Table H summarizes results of re-fitting the “reduced” model from Supplementary Table 4. Only data for the reference BP and in-procedure mean BP are 
shown. All other effects (excursion rates, Thrombolysis in Cerebral Infarction [TICI] grade, stroke etiology, history of coronary artery disease) were consistently 
virtually identical as in Supplementary Table 4.
The interaction term between reference SBP/MAP and in-procedure mean SBP/MAP (mean-centered) was highly insignificant; however, in this model esti-
mated effects of the reference BP on the odds of post-procedure hemorrhages were considerably changed as they became highly imprecise and statistically 
insignificant, whereas the effect of in-procedure mean BP remained closely similar as in the starting “reduced” model.
When in-procedure mean BP was removed from the model, reference BP was no longer associated with the odds of post-procedure hemorrhages. When 
reference BP was removed from the model, in-procedure mean BP was no longer associated with the odds of post-procedure hemorrhages.
2. Mediation analysis
Results are summarized in Table I. The results were consistent in the model for SBP and the model for MAP. Higher reference BP (predictor) was directly asso-
ciated with higher in-procedure mean BP (mediator). This is in line with the results of the Supplementary Analysis of Blood Pressure (Table F). Higher in-pro-
cedure mean BP was directly associated with lower odds of post-procedure hemorrhages (with the adjustment for reference BP and other effects). This is line 
with the results of the “reduced” model in Supplementary Table 4. Higher reference BP (predictor) tended towards direct association with higher odds of post-
procedure hemorrhages (outcome), but this association did not attain statistical significance. This is in line with the results of the “reduced” model in Supple-
mentary Table 4. Namely, when a predictor and a mediator are simultaneously included in a “common” regression model (as is the “reduced” model in Supple-
mentary Table 4), their individual direct associations with the outcome are quantified. Mediation analysis, using a set of consecutive regressions, partials-out 
direct and indirect associations (through a mediator) between the predictor and the outcome. As depicted in Table I, in both models (SBP/MAP), higher refer-
ence BP tended to be associated with lower odds of post-procedure hemorrhages, indirectly via its association with higher in-procedure mean BP, thus illus-
trating a phenomenon of “inconsistent mediation” (the direct and mediated effects are in an opposite direction). Consequently, in both models (SBP, MAP), the 
total effect (combined direct and indirect) of the reference BP (predictor) on the outcome was close to zero (direct and indirect effects mutually cancelled-
out). This is in line with the results of the re-fitted “reduced” model that did not include in-procedure mean BP (Table H): in a “common” regression model 
that does not include the mediator, effect of a predictor on the outcome corresponds to a total effect from the mediation analysis (i.e., the direct effect is not 
partialed-out).
Overall, the present analysis suggests that the observed opposite associations of the reference BP and of in-procedure mean BP with the probability of post-
procedure hemorrhages in the “reduced” model in Supplementary Table 4, although apparently counterintuitive, can be explained by their mutual relationship. 
In terms of their practical meaning, the results of the “reduced” model in Supplementary Table 4 require cautious interpretation in which several facts need to 
be considered. Firstly, regarding the temporal sequence of events, reference BP precedes the in-procedure BP. Next, the two BP indices are driven by different 
factors. As shown in the Supplementary Analysis of Blood Pressure, reference BP results from (is defined by) on-admission BP and, in part, from measures un-
dertaken in order to drive it into the limits recommended for the reperfusion procedure (Table D, Figure A). In-procedure mean BP, on the other hand, is largely 
determined by the reference BP in several ways: (a) higher reference BP is associated with higher in-procedure mean BP (Supplementary Analysis of Blood 
Pressure, Table F). This appears reasonable within the context of EVT: the procedure starts only after BP (reference BP) has been driven within the recom-
mended boundaries, and BP is then maintained around this (preferred) value. Hence, higher the reference (within the recommendations)—higher the proce-
dure mean BP; (b) in-procedure mean BP is also largely determined by the rate of BP excursions—higher the rate of excursions to >120% of the reference, 
higher the in-procedure mean; higher the rate of excursions to <80%, lower the in-procedure mean (Supplementary Analysis of Blood Pressure, Table F). Ref-
erence BP influences the in-procedure mean BP also by “driving” the rate of BP excursions: higher the reference BP, lower the risk of BP excursions to >120% 
of the reference and higher the risk of excursions to <80% of the reference (Supplementary Analysis of Blood Pressure, Table G). Therefore, in the context of 
EVT, with defined recommended pre-EVT BP values, reference BP is a milestone that defines the subsequent (during EVT) BP management, i.e., tolerance to-
wards the oscillations, measures to reduce/control them. In this respect, the relationship between reference BP and post-procedure hemorrhages should pref-
erably (as this is in line with the sequence of events) be viewed “through” the in-procedure mean BP. Hence, the main observation arising from the “reduced” 
model in Supplementary Table 4 is the association between higher in-procedure BP and lower odds of hemorrhages. Whatever effect reference BP “in itself” 
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might have on the risk of post-procedure hemorrhages, this is cancelled-out by the subsequent in procedure BP: this is supported by the lack of a total effect 
of the reference BP in the mediation analysis due to opposing direct and mediated effects, and a lack of the effect of the reference BP in a “common” regres-
sion model when in-procedure mean is not accounted for (i.e., when the direct effect is not partialed-out from the total effect, i.e., when it is not separated 
from the indirect effect). This reasoning might be objected in the light of the fact that under similar conditions (re-fitted “reduced” model without an account 
for reference BP), in-procedure mean BP was also not associated with the odds of hemorrhages (Table H). In this respect, one should have in mind the specific 
temporal (reference BP precedes the in-procedure BP) and causal (reference BP determines in-procedure mean BP, and not vice versa) relationship between 
the reference and in-procedure BP. In this re-fitted model, one actually observes a “total” effect of in-procedure mean BP, i.e., this is a situation in which its 
specific direct effect on the risk of hemorrhages is not partialed-out from the total effect that it carries. Since it is cardinally determined by the reference BP, 
this total effect of the in-procedure mean BP actually largely represents the total effect of the reference BP (which is close to zero). It follows that in “com-
mon” regression models that exclude reference BP, one cannot actually identify the effect of in-procedure mean BP on the outcome (due to the strong causal 
relationship between the two). 
Table H. Summary of the re-fitted versions of the “reduced” logistic model from Supplementary Table 4 analyzing association between reference BP and in-
procedure weighted mean BP and occurrence of post-procedure hemorrhages
Variable
Systolic blood pressure Mean arterial pressure
OR (95% CI) P OR (95% CI) P
Reference BP (by 10 mm Hg) 1.48 (0.99–2.28) 0.056 1.86 (1.00–3.47) 0.051
In-procedure mean BP (by 10 mm Hg) 0.65 (0.40–0.96) 0.032 0.52 (0.26–0.95) 0.034
+Reference BP*in-procedure mean BP interaction
Reference BP*in-procedure mean BP interaction 0.99 (0.98–1.00) 0.206 1.00 (0.98–1.01) 0.669
Reference BP (by 10 mm Hg) 3.94 (0.81–19.0) 0.088 2.66 (0.45–15.6) 0.278
In-procedure mean BP (by 10 mm Hg) 0.64 (0.42–0.99) 0.046 0.51 (0.27–0.96) 0.039
In-procedure mean BP excluded
Reference BP (by 10 mm Hg) 1.05 (0.83–1.32) 0.686 1.06 (0.77–1.46) 0.720
Reference BP excluded
In-procedure mean BP (by 10 mm Hg) 0.89 (0.71–1.14) 0.379 0.88 (0.65–1.21) 0.441
It is extension of model from Supplementary Table 4. In-procedure mean BP (by 10 mm Hg) is added to models from Supplementary Table 4, that's why there 
is a plus sign.
BP, blood pressure; OR, odds ratio; CI, confidence interval.
Table I. Summary of the mediation analysis: effects are shown as regression coefficients
Effects β (95% CI); P
Model for SBP
Predictor (reference BP) → mediator (in-procedure mean BP) 0.82 (0.73 to 0.91); <0.001
Mediator → outcome (odds of post-procedure hemorrhages) –0.0059 (–0.0116 to –0.0002); 0.043
Direct effect predictor → outcome 0.0056 (–0.0001 to 0.0113); 0.056
Indirect effect predictor → outcome via mediator –0.0048 (–0.0094 to 0.0015); 0.078
Total effect (direct+indirect) predictor → outcome 0.0007 (–0.0026 to 0.0040); 0.661
Model for MAP
Predictor (reference BP) → mediator (in-procedure mean BP) 0.86 (0.78–0.94); <0.001
Mediator → outcome (odds of post-procedure hemorrhages) –0.0084 (–0.0168 to –0.0000); 0.050
Direct effect predictor → outcome 0.0082 (–0.0005 to 0.0169); 0.060
Indirect effect predictor → outcome via mediator –0.0073 (–0.0150 to 0.0020); 0.099
Total effect (direct+indirect) predictor → outcome 0.0010 (–0.0035 to 0.0055); 0.678
CI, confidence interval; SBP, systolic blood pressure; BP, blood pressure; MAP, mean arterial pressure.
